{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 88930, "items": [{"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T17:26:18Z", "timestamp": 1575221178071}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 5, 1]], "date-time": "2013-05-01T00:00:00Z", "timestamp": 1367366400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia Research"], "published-print": {"date-parts": [[2013, 5]]}, "DOI": "10.1016/s0145-2126(13)70076-6", "type": "journal-article", "created": {"date-parts": [[2013, 5, 9]], "date-time": "2013-05-09T07:33:16Z", "timestamp": 1368084796000}, "page": "S34-S35", "source": "Crossref", "is-referenced-by-count": 0, "title": ["P-027 Recurrent SETBP1 mutations in atypical chronic myeloid leukemia"], "prefix": "10.1016", "volume": "37", "author": [{"given": "R.", "family": "Piazza", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Valletta", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Winkelmann", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Redaelli", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Spinelli", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Pirola", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Antolini", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Mologni", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Donadoni", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Papaemmanuil", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Schnittger", "sequence": "additional", "affiliation": []}, {"given": "D.W.", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Boultwood", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Rossi", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Gaipa", "sequence": "additional", "affiliation": []}, {"given": "G.P.", "family": "De Martini", "sequence": "additional", "affiliation": []}, {"given": "P.F.", "family": "Di Celle", "sequence": "additional", "affiliation": []}, {"given": "H.G.", "family": "Jang", "sequence": "additional", "affiliation": []}, {"given": "V.", "family": "Fantin", "sequence": "additional", "affiliation": []}, {"given": "G.R.", "family": "Bignell", "sequence": "additional", "affiliation": []}, {"given": "V.", "family": "Magistroni", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Haferlach", "sequence": "additional", "affiliation": []}, {"given": "E.M.", "family": "Pogliani", "sequence": "additional", "affiliation": []}, {"given": "P.J.", "family": "Campbell", "sequence": "additional", "affiliation": []}, {"given": "A.J.", "family": "Chase", "sequence": "additional", "affiliation": []}, {"given": "W.J.", "family": "Tapper", "sequence": "additional", "affiliation": []}, {"given": "N.C.", "family": "Cross", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Gambacorti-Passerini", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Leukemia Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0145212613700766?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0145212613700766?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 16]], "date-time": "2018-10-16T04:28:12Z", "timestamp": 1539664092000}, "score": 40.562675, "issued": {"date-parts": [[2013, 5]]}, "references-count": 0, "alternative-id": ["S0145212613700766"], "URL": "http://dx.doi.org/10.1016/s0145-2126(13)70076-6", "ISSN": ["0145-2126"], "issn-type": [{"value": "0145-2126", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:27:47Z", "timestamp": 1575530867700}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 11, 15]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Atypical Chronic Myeloid Leukemia (aCML) is a clonal disorder belonging to the group of myelodysplastic/myeloproliferative (MDS/MPN) syndromes. In aCML many clinical features suggest the diagnosis of CML, however the lack of the BCR-ABL1 fusion point to a different pathogenetic process.</jats:p>\n               <jats:p>Recently, we identified the presence of clonal somatic mutations occurring in the SETBP1 gene in approximately 25% of aCML samples (Piazza R. et al., Nat Genet. 2013 Jan;45(1):18-24). A subsequent study (Maxson J. et al., N Engl J Med. 2013 May 9;368(19):1781-90) demonstrated the presence of somatic mutations of the CSF3R gene in Chronic Neutrophilic Leukemia (CNL) and, with lower frequency, in aCML. In a recent follow-up of the first study (Gotlib J. et al., Blood. 2013 Jul 29), the presence of both CSF3R and SETBP1 variants was tested in a cohort of 9 CNL and 20 aCML cases, demonstrating the presence of CSF3R somatic mutations in 40% of the aCML patients. Of these mutations, 20% were membrane, 5% truncating and 15% compound variants. Interestingly, 5% of the aCML patients showed coexistence of CSF3R and SETBP1 mutations, suggesting that variants occurring in these genes are not mutually exclusive.</jats:p>\n               <jats:p>To gain further insight into the relationship between CSF3R and SETBP1 in aCML, we extended our initial study by analyzing an expanded cohort of 65 aCML plus a total of 230 AML, ALL, CLL, CML, PV, TE, MMM, CMML and MDS cases for the presence of CSF3R and SETBP1 mutations. In line with previous findings (Piazza R. et al., Nat Genet. 2013 Jan;45(1):18-24; Maxson J. et al., N Engl J Med. 2013 May 9;368(19):1781-90), we found evidence of SETBP1 and/or CSF3R mutations only in MDS/MPN disorders. In aCML we identified a total of 18 (27.7%) mutations occurring in SETBP1 and 8 (12.3%) in the CSF3R gene. A large fraction (94.4 %) of the SETBP1 mutations was clustered in a 14 amino acid stretch that is also mutated in the Schinzel-Giedion syndrome, as previously reported (Piazza R. et al., Nat Genet. 2013 Jan;45(1):18-24). Of the 8 CSF3R mutations 5 were membrane proximal (4 T618I and 1 T615A) and 3 were truncating (2 Q776X and 1 Q781X). In 2 aCML samples we detected the coexistence of CSF3R and SETBP1 mutations. In both cases the CSF3R variant was a membrane proximal mutation; CSF3R and SETBP1 mutations were at comparable levels at the time of detection, therefore no conclusion can be drawn about the timing of the two mutational events.</jats:p>\n               <jats:p>Taken globally these data indicate that somatic mutations occurring in SETBP1 and CSF3R are present in aCML and can coexist. Interestingly, the frequency of the CSF3R mutations in our aCML cohort is largely different from that of Maxson and colleagues (12.3 vs 40%), although the frequency of the combined CSF3R/SETBP1 mutations is similar (3.1 vs 5%): the reasons for this discrepancy are actually unclear. Previously we demonstrated that the presence of SETBP1 mutations in aCML is an independent negative prognostic factor (Piazza R. et al., Nat Genet. 2013 Jan;45(1):18-24). Further studies with larger cohorts will be required to assess the prognostic impact of concurrent SETBP1 and CSF3R mutations.</jats:p>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>Cross: Novartis: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria. Gambacorti-Passerini:Pfizer, BMS: Consultancy, Consultancy Other; Pfizer: Research Funding.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v122.21.2598.2598", "type": "journal-article", "created": {"date-parts": [[2019, 10, 14]], "date-time": "2019-10-14T02:29:26Z", "timestamp": 1571020166000}, "page": "2598-2598", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["SETBP1 and CSF3R Mutations In Atypical Chronic Myeloid Leukemia"], "prefix": "10.1182", "volume": "122", "author": [{"given": "Rocco", "family": "Piazza", "sequence": "first", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy,"}]}, {"given": "Sara", "family": "Redaelli", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy,"}]}, {"given": "Simona", "family": "Valletta", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy,"}]}, {"given": "Alessandra", "family": "Pirola", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy,"}]}, {"given": "Roberta", "family": "Spinelli", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy,"}]}, {"given": "Vera", "family": "Magistroni", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy,"}]}, {"given": "Dong-Wook", "family": "Kim", "sequence": "additional", "affiliation": [{"name": "Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea,"}]}, {"given": "Nicholas C.P.", "family": "Cross", "sequence": "additional", "affiliation": [{"name": "Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom,"}]}, {"given": "Carlo", "family": "Gambacorti-Passerini", "sequence": "additional", "affiliation": [{"name": "Unit\u00e0 di Ricerca Clinica - Ematologia, Azienda Ospedaliera San Gerardo/University of Milano Bicocca, Monza, Italy"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/122/21/2598/11716/SETBP1-and-CSF3R-Mutations-In-Atypical-Chronic", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/122/21/2598/11716/SETBP1-and-CSF3R-Mutations-In-Atypical-Chronic", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T05:18:13Z", "timestamp": 1573881493000}, "score": 38.804085, "issued": {"date-parts": [[2013, 11, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2013, 11, 15]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v122.21.2598.2598", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:51:08Z", "timestamp": 1575528668502}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2014, 12, 6]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p />\n               <jats:p>INTRODUCTION: Atypical Chronic Myeloid Leukemia (aCML) is a heterogeneous disorder belonging to the group of myelodysplastic/myeloproliferative syndromes, characterized by a poor prognosis with a median survival time of 37 months. In 2013, by applying Next Generation Sequencing (NGS) technologies on 8 aCML cases, we demonstrated the presence of a recurrent somatic mutations in the SETBP1 gene (Piazza et al, Nat Gen 2013). SETBP1 mutations were identified in approximately 30% of aCML cases.</jats:p>\n               <jats:p>AIM: To further characterize the molecular pathogenesis of aCML and to possibly identify other recurrent lesions responsible for SETBP1 unmutated cases, we extended our initial NGS effort: we applied whole-exome and transcriptome sequencing to a total of 16 matched samples taken at onset of the disease.</jats:p>\n               <jats:p>MATERIAL and METHODS: Whole-exome and transcriptome sequencing data were generated using an Illumina Genome Analyzer IIx following standard library-preparation protocols. Alignment to the reference GRCh37/hg19 genome was performed using BWA. Alignment data were processed using Samtools. Single nucleotide and small indel detection was performed using in-house software. Copy number analyses from whole-exome data were generated using CEQer (Piazza et al, PLoS One 2013) and gene fusions transcriptome data were screened using FusionAnalyser (Piazza et al, Nucleic Acids Res. 2012).</jats:p>\n               <jats:p>RESULTS: The application of NGS techniques to the cohort of aCML cases led to the identification of a somatic, non-synonymous single-nucleotide mutation (chr4:g.55599321A&gt;T) in the KIT gene in 1/16 (6%) cases. At protein level this mutation translated into the D816V variant that has been already described in several clonal disorders, such as systemic mastocytosis, gastrointestinal stromal tumors and acute myeloid leukemia.</jats:p>\n               <jats:p>To assess whether the mutation identified by NGS was recurrent, we extended our analysis by targeted resequencing on a larger cohort of 68 aCML cases. This analysis revealed the presence of KIT mutations in 3 additional patients, thus confirming the recurrence of KIT variants in aCML. All the KIT mutations identified correspond to the D816V that is responsible for the constitutive activation of the tyrosine kinase. This finding suggests that the activation of the KIT tyrosine kinase signaling may play an important role in this subset of aCML patients. It is known from the literature that KIT D816V is highly sensitive to the tyrosine kinase inhibitor dasatinib (Schittenhelm MM, Cancer Res 2006). To test whether dasatinib is able to affect the growth of the leukemic clone in KIT mutated aCML cases, we performed ex vivo tritiated thymidine proliferation assays on bone marrow (BM) cells from one of the KIT D816V positive aCML patients in presence of either dasatinib, imatinib or vehicle alone: the proliferation assay showed that dasatinib was able to inhibit the proliferation of the leukemic clone with an IC50 of 1nM, while, as expected, neither imatinib nor vehicle alone were able to significantly impair cell growth. In line with these data, western blot with an anti- Phospho-KIT antibody on KIT+ lysates after treatment with increasing concentration of dasatinib showed that the drug was highly effective in inhibiting KIT autophosphorylation. To further confirm the inhibitory activity of dasatinib, we performed a colony assay on peripheral blood cells from a KIT D816V positive aCML patient grown in presence of increasing concentrations of the drug: treatment with 100nM dasatinib was able to completely inhibit cell growth, leading to a virtually complete absence of colonies in the D816V-positive plates.</jats:p>\n               <jats:p>CONCLUSION: These data indicate that KIT D816V is a pro-oncogenic lesion recurrently present in aCML, albeit with low frequency (5/84, 6%) and that aCML cells bearing this mutation are highly sensitive to dasatinib, at least ex vivo. Given the very poor prognosis of this disorder, these findings suggest a new, highly efficient targeted treatment for a subset of aCML patients.</jats:p>\n               <jats:sec>\n                  <jats:title>Disclosures</jats:title>\n                  <jats:p>Schnittger: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Meggendorfer:MLL Munich Leukemia Laboratory: Employment.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v124.21.3576.3576", "type": "journal-article", "created": {"date-parts": [[2019, 10, 11]], "date-time": "2019-10-11T02:01:58Z", "timestamp": 1570759318000}, "page": "3576-3576", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia"], "prefix": "10.1182", "volume": "124", "author": [{"given": "Sara", "family": "Redaelli", "sequence": "first", "affiliation": [{"name": "University of Milano Bicocca, Monza, Italy"}]}, {"given": "Rocco", "family": "Piazza", "sequence": "additional", "affiliation": [{"name": "University of Milano Bicocca, Monza, Italy"}]}, {"given": "Alessandra", "family": "Pirola", "sequence": "additional", "affiliation": [{"name": "University of Milano Bicocca, Monza, Italy"}]}, {"given": "Vera", "family": "Magistroni", "sequence": "additional", "affiliation": [{"name": "University of Milano Bicocca, Monza, Italy"}]}, {"given": "Susanne", "family": "Schnittger", "sequence": "additional", "affiliation": [{"name": "MLL Munich Leukemia Laboratory, Munich, Germany"}]}, {"given": "Manja", "family": "Meggendorfer", "sequence": "additional", "affiliation": [{"name": "MLL Munich Leukemia Laboratory, Munich, Germany"}]}, {"given": "Nicholas C.P.", "family": "Cross", "sequence": "additional", "affiliation": [{"name": "University of Southampton, Salisbury, United Kingdom"}]}, {"given": "Delphine", "family": "Rea", "sequence": "additional", "affiliation": [{"name": "Hopital Saint-Louis, Paris, France"}]}, {"given": "Carlo", "family": "Gambacorti-Passerini", "sequence": "additional", "affiliation": [{"name": "University of Milano-Bicocca, Monza, Italy"}, {"name": "San Gerardo Hospital, Monza, Italy"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/124/21/3576/97795/Recurrent-KIT-D816V-Mutation-in-Atypical-Chronic", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/124/21/3576/97795/Recurrent-KIT-D816V-Mutation-in-Atypical-Chronic", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T03:51:01Z", "timestamp": 1574049061000}, "score": 36.520515, "issued": {"date-parts": [[2014, 12, 6]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2014, 12, 6]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v124.21.3576.3576", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:49:40Z", "timestamp": 1575528580896}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "23", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2015, 12, 3]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Atypical Chronic Myeloid Leukemia (aCML) is a clonal disorder belonging to the myelodisplastic-myeloproliferative neoplasms, according to the WHO-2008 classification. From a clinical point of view it closely resembles the classical Chronic Myeloid Leukemia (CML), however it lacks the presence of the Philadelphia chromosome and of the BCR-ABL1 fusion gene.</jats:p>\n               <jats:p>In recent works, we and others characterized the somatic lesions present in the aCML genome, mainly by using Next Generation Sequencing (NGS) technologies, demonstrating the presence of a large set of recurrent somatic mutations involving, among the others, SETBP1, ETNK1, ASXL1, EZH2, CBL, TET2, NRAS and U2AF1 genes. The identification of somatic variants occurring in a large number of genes clearly indicates that the genetic bases of aCML are very heterogeneous, in striking contrast with classical CML.</jats:p>\n               <jats:p>This heterogeneity poses a great challenge to the dissection of the molecular steps required for aCML leukemogenesis. The hierarchical reconstruction of the different mutations occurring in a clonal disorder can have important biological, prognostic and therapeutic repercussions; therefore we started a project focused on the dissection of the aCML clonal evolution steps through the analysis of individual leukemic clones by methylcellulose assays in samples whose mutational status has been previously characterized by matched whole-exome sequencing.</jats:p>\n               <jats:p>Patient CMLPh-019 was characterized by the presence of a complex mutational status, with somatic variants occurring in SETBP1, ETNK1, ASXL1 and CBL genes (Fig. 1a). Targeted resequencing analysis of individual clones revealed the presence of all the 4 variants in 44/60 (73.3%) clones; in 15/60 (25%) we detected the presence of mutated ETNK1, ASXL1 and CBL and wild-type (WT) SETBP1. Of these 15 clones, 33% carried heterozygous and 67% homozygous CBL mutations. In one clone (1.7%) we detected heterozygous ETNK1, homozygous CBL and WT sequences for ASXL1 and SETBP1, suggesting a strong selective pressure towards the acquisition of homozygous CBL mutations. Identification of homozygous CBL mutations in all the main clonal phases suggests that a significant positive selective pressure is associated with this event. Allelic imbalance analysis of CMLPh-019 exome using CEQer revealed that CBL homozygosity is caused by a somatic uniparental disomy event occurring in the telomeric region of the long arm of chromosome 11.</jats:p>\n               <jats:p>Patient CMLPh-005 (Fig. 1b) was mutated in ASXL1, CBL and SETBP1. Targeted analysis done on 68 clones revealed a complex, branching evolution, with 63 clones carrying all the 3 variants. Of them, 47 (74.6%) had a heterozygous and 16 (25.4%) a homozygous CBL variant. Four clones (4.2%) carried ASXL1 and SETBP1 but not CBL mutations, while 1 clone was mutated in ASXL1 and CBL in absence of SETBP1 mutations, which suggests that CBL mutations occurred independently in two different subclones. Also in this case, allelic imbalance analysis of exome data revealed that CBL homozygosity was caused by a telomeric somatic uniparental disomy event.</jats:p>\n               <jats:p>According to exome sequencing, patient CMLPh-003 carried SETBP1 mutation G870S and NRAS variant G12R. Clonal analysis confirmed the presence of SETBP1 G870S in all the clones analyzed, while heterozygous NRAS G12R mutation was detected in 67% (Fig. 1c). Notably in the remaining 33% another heterozygous NRAS variant, G12D, was detected. Retrospective reanalysis of exome data confirmed the presence of the newly identified variant, which had been previously filtered-out from exome data because of the low frequency.</jats:p>\n               <jats:p>Patient CMLPh-013 was mutated in ASXL1, ETNK1, NRAS and SETBP1. Of the 39 clones analyzed, 34 (82.9%) showed the coexistence of ASXL1, ETNK1, NRAS and SETBP1, 4 were mutated in ASXL1, ETNK1 and NRAS and 1 in ETNK1 and NRAS, suggesting that ETNK1 and NRAS were early events, ASXL1 an intermediate one and SETBP1 a late variant (Fig. 1d).</jats:p>\n               <jats:p>Taken globally, these data indicate that ETNK1 variants occur very early in the clonal evolution history of aCML, while ASXL1 represents an early/intermediate event and SETBP1 is often a late event. They also suggest that, in the context of aCML, there is a strong selective pressure towards the accumulation of homozygous CBL variants, as already shown in other leukemias.</jats:p>\n               <jats:p>Figure 1. Clonal analysis of four aCML cases. The asterisks indicate hypothetical clones. Figure 1. Clonal analysis of four aCML cases. The asterisks indicate hypothetical clones.</jats:p>\n               <jats:sec>\n                  <jats:title>Disclosures</jats:title>\n                  <jats:p>Rea: Novartis: Honoraria; Bristol-Myers Squibb: Honoraria; Pfizer: Honoraria; Ariad: Honoraria.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v126.23.3652.3652", "type": "journal-article", "created": {"date-parts": [[2019, 10, 10]], "date-time": "2019-10-10T23:28:05Z", "timestamp": 1570750085000}, "page": "3652-3652", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia"], "prefix": "10.1182", "volume": "126", "author": [{"given": "Antonio", "family": "Niro", "sequence": "first", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Rocco", "family": "Piazza", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Gabriele", "family": "Merati", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Alessandra", "family": "Pirola", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Carla", "family": "Donadoni", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Diletta", "family": "Fontana", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Sara", "family": "Redaelli", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Caterina", "family": "Mezzatesta", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Rossella", "family": "Renso", "sequence": "additional", "affiliation": [{"name": "San Gerardo Hospital, Unit of Hematology, Monza, Italy"}]}, {"given": "Francesca", "family": "Farina", "sequence": "additional", "affiliation": [{"name": "San Gerardo Hospital, Unit of Hematology, Monza, Italy"}]}, {"given": "Delphine", "family": "Rea", "sequence": "additional", "affiliation": [{"name": "Hematology department, H\u00f4pital Saint-Louis, Paris, France"}]}, {"given": "Carlo", "family": "Gambacorti-Passerini", "sequence": "additional", "affiliation": [{"name": "Dept. of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/126/23/3652/93100/ETNK1-Is-an-Early-Event-and-SETBP1-a-Late-Event-in", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/126/23/3652/93100/ETNK1-Is-an-Early-Event-and-SETBP1-a-Late-Event-in", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 17]], "date-time": "2019-11-17T09:33:21Z", "timestamp": 1573983201000}, "score": 33.868828, "issued": {"date-parts": [[2015, 12, 3]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2015, 12, 3]]}, "issue": "23"}, "URL": "http://dx.doi.org/10.1182/blood.v126.23.3652.3652", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:59:49Z", "timestamp": 1574539189828}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 4, 15]]}, "DOI": "10.1158/1538-7445.am2013-3176", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:46:55Z", "timestamp": 1408056415000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 3176: Recurrent SETBP1 mutations in atypical chronic myeloid leukemia abrogate an ubiquitination site and dysregulate SETBP1 protein levels."], "prefix": "10.1158", "author": [{"given": "Rocco", "family": "Piazza", "sequence": "first", "affiliation": []}, {"given": "Simona", "family": "Valletta", "sequence": "additional", "affiliation": []}, {"given": "Nils", "family": "Winkelmann", "sequence": "additional", "affiliation": []}, {"given": "Sara", "family": "Redaelli", "sequence": "additional", "affiliation": []}, {"given": "Roberta", "family": "Spinelli", "sequence": "additional", "affiliation": []}, {"given": "Alessandra", "family": "Pirola", "sequence": "additional", "affiliation": []}, {"given": "Laura", "family": "Antolini", "sequence": "additional", "affiliation": []}, {"given": "Luca", "family": "Mologni", "sequence": "additional", "affiliation": []}, {"given": "Carla", "family": "Donadoni", "sequence": "additional", "affiliation": []}, {"given": "Elli", "family": "Papaemmanuil", "sequence": "additional", "affiliation": []}, {"given": "Susanne", "family": "Schnittger", "sequence": "additional", "affiliation": []}, {"given": "Kim", "family": "Dong-Wook", "sequence": "additional", "affiliation": []}, {"given": "Jacqueline", "family": "Boultwood", "sequence": "additional", "affiliation": []}, {"given": "Fabio", "family": "Rossi", "sequence": "additional", "affiliation": []}, {"given": "Giuseppe", "family": "Gaipa", "sequence": "additional", "affiliation": []}, {"given": "Greta", "family": "De Martini", "sequence": "additional", "affiliation": []}, {"given": "Paola Francia", "family": "di Celle", "sequence": "additional", "affiliation": []}, {"given": "Hyun Gyung", "family": "Jang", "sequence": "additional", "affiliation": []}, {"given": "Valeria", "family": "Fantin", "sequence": "additional", "affiliation": []}, {"given": "Graham R.", "family": "Bignell", "sequence": "additional", "affiliation": []}, {"given": "Vera", "family": "Magistroni", "sequence": "additional", "affiliation": []}, {"given": "Torsten", "family": "Haferlach", "sequence": "additional", "affiliation": []}, {"given": "Enrico Maria", "family": "Pogliani", "sequence": "additional", "affiliation": []}, {"given": "Peter", "family": "Campbell", "sequence": "additional", "affiliation": []}, {"given": "Andrew J.", "family": "Chase", "sequence": "additional", "affiliation": []}, {"given": "William J.", "family": "Tapper", "sequence": "additional", "affiliation": []}, {"given": "Nick C.P.", "family": "Cross", "sequence": "additional", "affiliation": []}, {"given": "Carlo", "family": "Gambacorti Passerini", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 18]]}, "event": {"name": "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC"}, "container-title": ["Molecular and Cellular Biology"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2013-3176", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T20:11:50Z", "timestamp": 1558210310000}, "score": 33.72619, "issued": {"date-parts": [[2013, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2013-3176"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2013-3176"}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:37:10Z", "timestamp": 1575527830104}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2012, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Abstract LBA-2</jats:p>\n               <jats:p>The SETBP1 gene codes for a predominantly nuclear protein with a predicted MW of 170 kD. Germline mutations of SETBP1 were described in patients affected by the Schinzel-Giedion syndrome (SGS), a rare disease characterized by bone, muscle and cardiac abnormalities, and presenting neuroepithelial neoplasms. In an effort to investigate the molecular pathogenesis of myeloid malignancies we applied a HTS strategy, including both exome sequencing and RNA-SEQ, to atypical Chronic Myeloid Leukemia (aCML), as defined by WHO criteria, with the aim of identifying novel recurrent driver mutations. aCML shares clinical and laboratory features with CML, but it lacks the pathognomonic BCR-ABL1fusion. Since no specific recurrent genomic or karyotypic abnormalities have been identified in aCML, the molecular pathogenesis of this disease has remained elusive and the outcome dismal (median survival 37 months) with no improvement over the last 20 years. This sharply contrasts with the outcome for CML, for which the prognosis was dramatically improved by the development of imatinib as a specific inhibitor of the BCR/ABL protein.</jats:p>\n               <jats:p>Whole-exome sequencing of 9 aCML patients revealed the presence of 62 unique mutations (range 5\u201314 per patient), including a recurrent alteration of SETBP1 (G870S and D868N) in three cases. Targeted resequencing performed in 70 aCMLs, 574 patients with different hematological malignancies and 344 cell lines, identified SETBP1 mutations in 17 of 70 aCML patients (24.3%; 95% CI: 16\u201335%), 4 of 30 (13%) MDS/MPN-u and 3 of 82 (3.6%) CMML patients.</jats:p>\n               <jats:p>Patients with mutations had higher white blood cell counts (p=0.008) and worse prognosis (p=0.01) when tested in multivariate analysis. TF1 cells transfected with SETBP1G870S showed increased SET levels, decreased PP2A activity and increased proliferation rates.</jats:p>\n               <jats:p>The vast majority of mutations (85%) was located between residues 858 and 871, in the SKI homologous region of SETBP1, and were identical to germline changes seen in patients with SGS. This region may be critical for ubiquitin binding and for subsequent protein degradation, since the Eukaryotic Linear Motif (ELM) identified with high probability score a putative functional site (aa. 868\u2013873) for beta-TrCP, the substrate recognition subunit of the E3 ubiquitin ligase. This prediction was experimentally validated using biotinylated, phosphorylated peptides encompassing this region (aa 859\u2013879): while the wild type peptide could efficiently bind beta-TrCP as predicted, a peptide presenting the G870S mutation was incapable of binding this E3 ligase subunit, indicating a possible alteration in SETBP1 protein stability caused by this mutation. In agreement with these findings, cells transfected with SETBP1G870Sshowed increased levels of SETBP1 protein when compared to cells with similar expression levels of the wild type gene.</jats:p>\n               <jats:p>Finally, RNA-SEQ yielded gene expression profiles with overrepresentation of genes under the control of Transforming Growth Factor Beta 1 (TGF\u03b21) among genes differentially expressed between SETBP1-mutated and unmutated aCML patients.</jats:p>\n               <jats:p>Mutated SETBP1 represents a novel type of oncogene which is specifically present in aCML and closely related diseases. These data allow for a better understanding of the molecular pathogenesis of this disease; they provide evidence that SETBP1 mutations might be a new biomarker for future diagnosis and classification of aCML and related diseases, and indicate a potential strategy to develop new treatment modalities for malignancies caused by mutated SETBP1.</jats:p>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>Schnittger: MLL Munich Leukemia Laboratory: Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v120.21.lba-2.lba-2", "type": "journal-article", "created": {"date-parts": [[2019, 10, 9]], "date-time": "2019-10-09T23:48:16Z", "timestamp": 1570664896000}, "page": "LBA-2-LBA-2", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels"], "prefix": "10.1182", "volume": "120", "author": [{"given": "Carlo", "family": "Gambacorti-Passerini", "sequence": "first", "affiliation": [{"name": "Hematology and Clinical Research Unit, San Gerardo Hospital, Monza, Italy"}]}, {"given": "Simona", "family": "Valletta", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Nils", "family": "Winkelmann", "sequence": "additional", "affiliation": [{"name": "Wessex Regional Genetics Laboratory, Salisbury, United Kingdom"}]}, {"given": "Sara", "family": "Redaelli", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Roberta", "family": "Spinelli", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Alessandra", "family": "Pirola", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Laura", "family": "Antolini", "sequence": "additional", "affiliation": [{"name": "Center of Biostatistics for Clinical Epidemiology, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Luca", "family": "Mologni", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Carla", "family": "Donadoni", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Elli", "family": "Papaemmanuil", "sequence": "additional", "affiliation": [{"name": "Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}]}, {"given": "Susanne", "family": "Schnittger", "sequence": "additional", "affiliation": [{"name": "MLL Munich Leukemia Laboratory, Munich, Germany"}]}, {"given": "Kim", "family": "Dong-Wook", "sequence": "additional", "affiliation": [{"name": "Division of Hematology, Seoul St. Mary\u2019s Hospital The Catholic University of Korea, Seul, South Korea"}]}, {"given": "Jacqueline", "family": "Boultwood", "sequence": "additional", "affiliation": [{"name": "Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}]}, {"given": "Fabio", "family": "Rossi", "sequence": "additional", "affiliation": [{"name": "Immunotransfusional Unit, San Gerardo Hospital, Monza, Italy"}]}, {"given": "Giuseppe", "family": "Gaipa", "sequence": "additional", "affiliation": [{"name": "M. Tettamanti Research Center, Pediatric Clinic University of Milano Bicocca, Monza, Italy"}]}, {"given": "Greta", "family": "De Martini", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Paola Francia", "family": "di Celle", "sequence": "additional", "affiliation": [{"name": "SCDU Anatomia Patologica II. Lab. Oncologia Molecolare c/o CeRMS, Az. Ospedaliera S.Giovanni Battista, Torino, Italy"}]}, {"given": "Hyun G.", "family": "Jang", "sequence": "additional", "affiliation": [{"name": "Agios Pharmaceuticals, Cambridge, MA, USA"}]}, {"given": "Valeria", "family": "Fantin", "sequence": "additional", "affiliation": [{"name": "Agios Pharmaceuticals, Cambridge, MA, USA"}]}, {"given": "Graham R", "family": "Bignell", "sequence": "additional", "affiliation": [{"name": "Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}]}, {"given": "Vera", "family": "Magistroni", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}, {"given": "Torsten", "family": "Haferlach", "sequence": "additional", "affiliation": [{"name": "MLL Munich Leukemia Laboratory, Munich, Germany"}]}, {"given": "Enrico Maria", "family": "Pogliani", "sequence": "additional", "affiliation": [{"name": "HSCT Adult Unit, Ospedale San Gerardo, Monza, Italy"}]}, {"given": "Peter", "family": "Campbell", "sequence": "additional", "affiliation": [{"name": "Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}]}, {"given": "Andrew J", "family": "Chase", "sequence": "additional", "affiliation": [{"name": "Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom"}]}, {"given": "William J", "family": "Tapper", "sequence": "additional", "affiliation": [{"name": "Wessex Regional Genetics Lab., University of Southampton, Salisbury, United Kingdom"}]}, {"given": "Nicholas C.P.", "family": "Cross", "sequence": "additional", "affiliation": [{"name": "Wessex Regional Genetics Laboratory, University of Southampton, Southamptom, United Kingdom"}]}, {"given": "Rocco", "family": "Piazza", "sequence": "additional", "affiliation": [{"name": "Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/120/21/LBA-2/87729/Recurrent-SETBP1-Mutations-in-Atypical-Chronic", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/120/21/LBA-2/87729/Recurrent-SETBP1-Mutations-in-Atypical-Chronic", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T17:08:41Z", "timestamp": 1573924121000}, "score": 33.72619, "issued": {"date-parts": [[2012, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2012, 11, 16]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v120.21.lba-2.lba-2", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T18:47:15Z", "timestamp": 1574880435969}, "reference-count": 0, "publisher": "Wiley", "content-domain": {"domain": []}, "published-print": {"date-parts": [[2019, 5, 4]]}, "DOI": "10.1002/hon.2638/v2/response1", "type": "peer-review", "created": {"date-parts": [[2019, 5, 21]], "date-time": "2019-05-21T17:05:29Z", "timestamp": 1558458329000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Author response for \"Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL)\""], "prefix": "10.1002", "author": [{"family": "R. Cassin", "sequence": "first", "affiliation": []}, {"family": "V. Mattiello", "sequence": "additional", "affiliation": []}, {"family": "M. Viltadi", "sequence": "additional", "affiliation": []}, {"family": "D. D'Aliberti", "sequence": "additional", "affiliation": []}, {"family": "R. Piazza", "sequence": "additional", "affiliation": []}, {"family": "C. Gambacorti\u2010Passerini", "sequence": "additional", "affiliation": []}, {"family": "U. Gianelli", "sequence": "additional", "affiliation": []}, {"family": "A. Neri", "sequence": "additional", "affiliation": []}, {"family": "A. Cortelezzi", "sequence": "additional", "affiliation": []}, {"family": "G. Reda", "sequence": "additional", "affiliation": []}], "member": "311", "review": {"type": "author-comment", "running-number": "A1V2", "revision-round": "2", "stage": "pre-publication"}, "deposited": {"date-parts": [[2019, 5, 21]], "date-time": "2019-05-21T17:05:31Z", "timestamp": 1558458331000}, "score": 30.493187, "issued": {"date-parts": [[2019, 5, 4]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1002/hon.2638/v2/response1", "relation": {"is-review-of": [{"id-type": "doi", "id": "10.1002/HON.2638", "asserted-by": "subject"}]}}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T13:07:44Z", "timestamp": 1575205664531}, "reference-count": 12, "publisher": "Springer Science and Business Media LLC", "issue": "10", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2013, 4, 5]], "date-time": "2013-04-05T00:00:00Z", "timestamp": 1365120000000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[2013, 10]]}, "DOI": "10.1038/leu.2013.97", "type": "journal-article", "created": {"date-parts": [[2013, 4, 5]], "date-time": "2013-04-05T09:47:10Z", "timestamp": 1365155230000}, "page": "2100-2102", "source": "Crossref", "is-referenced-by-count": 51, "title": ["SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML"], "prefix": "10.1038", "volume": "27", "author": [{"given": "R R", "family": "Laborde", "sequence": "first", "affiliation": []}, {"given": "M M", "family": "Patnaik", "sequence": "additional", "affiliation": []}, {"given": "T L", "family": "Lasho", "sequence": "additional", "affiliation": []}, {"given": "C M", "family": "Finke", "sequence": "additional", "affiliation": []}, {"given": "C A", "family": "Hanson", "sequence": "additional", "affiliation": []}, {"given": "R A", "family": "Knudson", "sequence": "additional", "affiliation": []}, {"given": "R P", "family": "Ketterling", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Pardanani", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Tefferi", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2013, 4, 5]]}, "reference": [{"key": "BFleu201397_CR1", "doi-asserted-by": "publisher", "first-page": "615", "DOI": "10.1182/blood-2009-06-227363", "volume": "115", "author": "I Cristobal", "year": "2010", "unstructured": "Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010; 115: 615\u2013625.", "journal-title": "Blood"}, {"key": "BFleu201397_CR2", "doi-asserted-by": "publisher", "first-page": "483", "DOI": "10.1038/ng.581", "volume": "42", "author": "A Hoischen", "year": "2010", "unstructured": "Hoischen A, van Bon BW, Gilissen C, Arts P, van Lier B, Steehouwer M et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet 2010; 42: 483\u2013485.", "journal-title": "Nat Genet"}, {"key": "BFleu201397_CR3", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1038/ng.2495", "volume": "45", "author": "R Piazza", "year": "2013", "unstructured": "Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18\u201324.", "journal-title": "Nat Genet"}, {"key": "BFleu201397_CR4", "doi-asserted-by": "publisher", "first-page": "1401", "DOI": "10.1038/leu.2013.35", "volume": "27", "author": "F Damm", "year": "2013", "unstructured": "Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013; 27: 1401\u20131403.", "journal-title": "Leukemia"}, {"key": "BFleu201397_CR5", "doi-asserted-by": "publisher", "first-page": "392", "DOI": "10.1200/JCO.2010.32.2446", "volume": "29", "author": "N Gangat", "year": "2011", "unstructured": "Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392\u2013397.", "journal-title": "J Clin Oncol"}, {"key": "BFleu201397_CR6", "doi-asserted-by": "publisher", "first-page": "1504", "DOI": "10.1038/leu.2013.88", "volume": "27", "author": "MM Patnaik", "year": "2013", "unstructured": "Patnaik MM, Padron E, Laborde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-Defined chronic myelomonocytic leukemia-ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27: 1504\u20131510.", "journal-title": "Leukemia"}, {"key": "BFleu201397_CR7", "doi-asserted-by": "publisher", "first-page": "375", "DOI": "10.3324/haematol.2010.030957", "volume": "96", "author": "E Such", "year": "2011", "unstructured": "Such E, Cervera J, Costa D, Sol\u00e9 F, Vallesp\u00ed T, Lu\u00f1o E et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011; 96: 375\u2013383.", "journal-title": "Haematologica"}, {"key": "BFleu201397_CR8", "doi-asserted-by": "publisher", "first-page": "840", "DOI": "10.1182/blood.V99.3.840", "volume": "99", "author": "F Onida", "year": "2002", "unstructured": "Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840\u2013849.", "journal-title": "Blood"}, {"key": "BFleu201397_CR9", "doi-asserted-by": "publisher", "first-page": "1351", "DOI": "10.1002/cncr.23697", "volume": "113", "author": "H Kantarjian", "year": "2008", "unstructured": "Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113: 1351\u20131361.", "journal-title": "Cancer"}, {"key": "BFleu201397_CR10", "doi-asserted-by": "publisher", "first-page": "48", "DOI": "10.1186/1756-8722-5-48", "volume": "5", "author": "F Albano", "year": "2012", "unstructured": "Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Minervini A et al. SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia. J Hematol Oncol 2012; 5: 48.", "journal-title": "J Hematol Oncol"}, {"key": "BFleu201397_CR11", "doi-asserted-by": "publisher", "first-page": "117", "DOI": "10.1136/jmg.2010.084582", "volume": "48", "author": "I Filges", "year": "2011", "unstructured": "Filges I, Shimojima K, Okamoto N, R\u00f6thlisberger B, Weber P, Huber AR et al. Reduced expression by SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a phenotype distinct from Schinzel-Giedion syndrome. J Med Genet 2011; 48: 117\u2013122.", "journal-title": "J Med Genet"}, {"key": "BFleu201397_CR12", "doi-asserted-by": "publisher", "first-page": "6099", "DOI": "10.1182/blood-2011-10-388710", "volume": "119", "author": "K Oakley", "year": "2012", "unstructured": "Oakley K, Han Y, Vishwakarma BA, Chu S, Bhatia R, Gudmundsson KO et al. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood 2012; 119: 6099\u20136108.", "journal-title": "Blood"}], "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/leu201397.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/leu201397", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/leu201397.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 18]], "date-time": "2019-04-18T21:15:18Z", "timestamp": 1555622118000}, "score": 30.081905, "issued": {"date-parts": [[2013, 4, 5]]}, "references-count": 12, "journal-issue": {"published-print": {"date-parts": [[2013, 10]]}, "issue": "10"}, "alternative-id": ["BFleu201397"], "URL": "http://dx.doi.org/10.1038/leu.2013.97", "relation": {"cites": []}, "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}], "subject": ["Anesthesiology and Pain Medicine", "Cancer Research", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 18]], "date-time": "2019-12-18T01:23:25Z", "timestamp": 1576632205379}, "reference-count": 33, "publisher": "Springer Science and Business Media LLC", "issue": "11", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2014, 4, 3]], "date-time": "2014-04-03T00:00:00Z", "timestamp": 1396483200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[2014, 11]]}, "DOI": "10.1038/leu.2014.125", "type": "journal-article", "created": {"date-parts": [[2014, 4, 3]], "date-time": "2014-04-03T06:39:28Z", "timestamp": 1396507168000}, "page": "2206-2212", "source": "Crossref", "is-referenced-by-count": 112, "title": ["ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients"], "prefix": "10.1038", "volume": "28", "author": [{"given": "M M", "family": "Patnaik", "sequence": "first", "affiliation": []}, {"given": "R", "family": "Itzykson", "sequence": "additional", "affiliation": []}, {"given": "T L", "family": "Lasho", "sequence": "additional", "affiliation": []}, {"given": "O", "family": "Kosmider", "sequence": "additional", "affiliation": []}, {"given": "C M", "family": "Finke", "sequence": "additional", "affiliation": []}, {"given": "C A", "family": "Hanson", "sequence": "additional", "affiliation": []}, {"given": "R A", "family": "Knudson", "sequence": "additional", "affiliation": []}, {"given": "R P", "family": "Ketterling", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Tefferi", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Solary", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2014, 4, 3]]}, "reference": [{"key": "BFleu2014125_CR1", "author": "S Swederlow", "year": "2008", "unstructured": "Swederlow S, Campo E, Harris NL, Jaffe ES, Stefano PA, Stein H et aleds WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.", "volume-title": "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues"}, {"key": "BFleu2014125_CR2", "doi-asserted-by": "publisher", "first-page": "273", "DOI": "10.1111/bjh.12756", "volume": "165", "author": "MM Patnaik", "year": "2014", "unstructured": "Patnaik MM, Parikh SA, Hanson CA, Tefferi A . Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 2014; 165: 273\u2013286.", "journal-title": "Br J Haematol"}, {"key": "BFleu2014125_CR3", "doi-asserted-by": "publisher", "first-page": "1401", "DOI": "10.1038/leu.2013.35", "volume": "27", "author": "F Damm", "year": "2013", "unstructured": "Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013; 27: 1401\u20131403.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR4", "doi-asserted-by": "publisher", "first-page": "788", "DOI": "10.1111/j.1365-2141.2009.07697.x", "volume": "145", "author": "V Gelsi-Boyer", "year": "2009", "unstructured": "Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788\u2013800.", "journal-title": "Br J Haematol"}, {"key": "BFleu2014125_CR5", "doi-asserted-by": "publisher", "first-page": "2428", "DOI": "10.1200/JCO.2012.47.3314", "volume": "31", "author": "R Itzykson", "year": "2013", "unstructured": "Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31: 2428\u20132436.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2014125_CR6", "doi-asserted-by": "publisher", "first-page": "2100", "DOI": "10.1038/leu.2013.97", "volume": "27", "author": "R Laborde", "year": "2013", "unstructured": "Laborde R, Patnaik M, Lasho T, Finke C, Hanson C, Knudson R et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia 2013; 27: 2100\u20132102.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR7", "doi-asserted-by": "publisher", "first-page": "3080", "DOI": "10.1182/blood-2012-01-404863", "volume": "120", "author": "M Meggendorfer", "year": "2012", "unstructured": "Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080\u20133088.", "journal-title": "Blood"}, {"key": "BFleu2014125_CR8", "doi-asserted-by": "publisher", "first-page": "1200", "DOI": "10.1038/leu.2011.58", "volume": "25", "author": "O Abdel-Wahab", "year": "2011", "unstructured": "Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25: 1200\u20131202.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR9", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1038/ng.2495", "volume": "45", "author": "R Piazza", "year": "2013", "unstructured": "Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18\u201324.", "journal-title": "Nat Genet"}, {"key": "BFleu2014125_CR10", "doi-asserted-by": "publisher", "first-page": "1504", "DOI": "10.1038/leu.2013.88", "volume": "27", "author": "MM Patnaik", "year": "2013", "unstructured": "Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27: 1504\u20131510.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR11", "doi-asserted-by": "publisher", "first-page": "1852", "DOI": "10.1038/leu.2013.133", "volume": "27", "author": "M Meggendorfer", "year": "2013", "unstructured": "Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013; 27: 1852\u20131860.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR12", "doi-asserted-by": "publisher", "first-page": "375", "DOI": "10.3324/haematol.2010.030957", "volume": "96", "author": "E Such", "year": "2011", "unstructured": "Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011; 96: 375\u2013383.", "journal-title": "Haematologica"}, {"key": "BFleu2014125_CR13", "doi-asserted-by": "publisher", "first-page": "840", "DOI": "10.1182/blood.V99.3.840", "volume": "99", "author": "F Onida", "year": "2002", "unstructured": "Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840\u2013849.", "journal-title": "Blood"}, {"key": "BFleu2014125_CR14", "doi-asserted-by": "publisher", "first-page": "4168", "DOI": "10.1182/blood-2012-05-429696", "volume": "120", "author": "TL Lasho", "year": "2012", "unstructured": "Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012; 120: 4168\u20134171.", "journal-title": "Blood"}, {"key": "BFleu2014125_CR15", "doi-asserted-by": "publisher", "first-page": "569", "DOI": "10.1182/blood-2011-09-377994", "volume": "119", "author": "MM Patnaik", "year": "2012", "unstructured": "Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119: 569\u2013572.", "journal-title": "Blood"}, {"key": "BFleu2014125_CR16", "doi-asserted-by": "publisher", "first-page": "64", "DOI": "10.1038/nature10496", "volume": "478", "author": "K Yoshida", "year": "2011", "unstructured": "Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64\u201369.", "journal-title": "Nature"}, {"key": "BFleu2014125_CR17", "doi-asserted-by": "publisher", "first-page": "1128", "DOI": "10.1038/leu.2010.69", "volume": "24", "author": "A Tefferi", "year": "2010", "unstructured": "Tefferi A . Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128\u20131138.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR18", "doi-asserted-by": "publisher", "first-page": "1656", "DOI": "10.1038/leu.2010.144", "volume": "24", "author": "O Abdel-Wahab", "year": "2010", "unstructured": "Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL . The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 2010; 24: 1656\u20131657.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR19", "doi-asserted-by": "publisher", "first-page": "12", "DOI": "10.1186/1756-8722-5-12", "volume": "5", "author": "V Gelsi-Boyer", "year": "2012", "unstructured": "Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D . Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012; 5: 12.", "journal-title": "J Hematol Oncol"}, {"key": "BFleu2014125_CR20", "doi-asserted-by": "publisher", "first-page": "2499", "DOI": "10.1200/JCO.2010.33.4938", "volume": "29", "author": "F Thol", "year": "2011", "unstructured": "Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499\u20132506.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2014125_CR21", "doi-asserted-by": "publisher", "first-page": "1062", "DOI": "10.1038/leu.2010.20", "volume": "24", "author": "J Boultwood", "year": "2010", "unstructured": "Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010; 24: 1062\u20131065.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR22", "doi-asserted-by": "publisher", "first-page": "2183", "DOI": "10.1038/leu.2009.141", "volume": "23", "author": "N Carbuccia", "year": "2009", "unstructured": "Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183\u20132186.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR23", "doi-asserted-by": "publisher", "first-page": "469", "DOI": "10.1038/leu.2009.218", "volume": "24", "author": "N Carbuccia", "year": "2010", "unstructured": "Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaide J et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010; 24: 469\u2013473.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR24", "doi-asserted-by": "publisher", "first-page": "2496", "DOI": "10.1056/NEJMoa1013343", "volume": "364", "author": "R Bejar", "year": "2011", "unstructured": "Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496\u20132506.", "journal-title": "N Engl J Med"}, {"key": "BFleu2014125_CR25", "doi-asserted-by": "publisher", "first-page": "1861", "DOI": "10.1038/leu.2013.119", "volume": "27", "author": "AM Vannucchi", "year": "2013", "unstructured": "Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861\u20131869.", "journal-title": "Leukemia"}, {"issue": "7", "key": "BFleu2014125_CR26", "doi-asserted-by": "publisher", "first-page": "1494", "DOI": "10.1038/leu.2014.57", "volume": "28", "author": "A Tefferi", "year": "2014", "unstructured": "Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; e-pub ahead of print 5 February 2014 doi:10.1038/leu.2014.57.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR27", "doi-asserted-by": "publisher", "first-page": "e85362", "DOI": "10.1371/journal.pone.0085362", "volume": "9", "author": "G Damaj", "year": "2014", "unstructured": "Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014; 9: e85362.", "journal-title": "PLoS One"}, {"key": "BFleu2014125_CR28", "doi-asserted-by": "publisher", "first-page": "2460", "DOI": "10.1182/blood-2013-04-496448", "volume": "122", "author": "J Schwaab", "year": "2013", "unstructured": "Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460\u20132466.", "journal-title": "Blood"}, {"key": "BFleu2014125_CR29", "doi-asserted-by": "publisher", "first-page": "1079", "DOI": "10.1056/NEJMoa1112304", "volume": "366", "author": "JP Patel", "year": "2012", "unstructured": "Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079\u20131089.", "journal-title": "N Engl J Med"}, {"key": "BFleu2014125_CR30", "doi-asserted-by": "publisher", "first-page": "82", "DOI": "10.1038/leu.2012.262", "volume": "27", "author": "S Schnittger", "year": "2013", "unstructured": "Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013; 27: 82\u201391.", "journal-title": "Leukemia"}, {"key": "BFleu2014125_CR31", "doi-asserted-by": "publisher", "first-page": "5593", "DOI": "10.1182/blood-2011-03-343988", "volume": "118", "author": "Y Shen", "year": "2011", "unstructured": "Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118: 5593\u20135603.", "journal-title": "Blood"}, {"key": "BFleu2014125_CR32", "doi-asserted-by": "publisher", "first-page": "6920", "DOI": "10.1182/blood-2011-08-368225", "volume": "118", "author": "KH Metzeler", "year": "2011", "unstructured": "Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118: 6920\u20136929.", "journal-title": "Blood"}, {"key": "BFleu2014125_CR33", "doi-asserted-by": "publisher", "first-page": "431", "DOI": "10.1038/leu.2013.286", "volume": "28", "author": "A Tefferi", "year": "2014", "unstructured": "Tefferi A, Finke CM, Lasho TL, Wassie EA, Knudson R, Ketterling RP et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 2014; 28: 431\u2013433.", "journal-title": "Leukemia"}], "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/leu2014125.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/leu2014125", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/leu2014125.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 18]], "date-time": "2019-04-18T15:50:40Z", "timestamp": 1555602640000}, "score": 29.67124, "issued": {"date-parts": [[2014, 4, 3]]}, "references-count": 33, "journal-issue": {"published-print": {"date-parts": [[2014, 11]]}, "issue": "11"}, "alternative-id": ["BFleu2014125"], "URL": "http://dx.doi.org/10.1038/leu.2014.125", "relation": {"cites": []}, "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}], "subject": ["Anesthesiology and Pain Medicine", "Cancer Research", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:28:47Z", "timestamp": 1574281727878}, "reference-count": 0, "publisher": "S. Karger AG", "issue": "4", "license": [{"URL": "https://www.karger.com/Services/SiteLicenses", "start": {"date-parts": [[1991, 1, 1]], "date-time": "1991-01-01T00:00:00Z", "timestamp": 662688000000}, "delay-in-days": 0, "content-version": "vor"}, {"URL": "https://www.karger.com/Services/SiteLicenses", "start": {"date-parts": [[1991, 1, 1]], "date-time": "1991-01-01T00:00:00Z", "timestamp": 662688000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Acta Haematol"], "published-print": {"date-parts": [[1991]]}, "DOI": "10.1159/000204837", "type": "journal-article", "created": {"date-parts": [[2009, 2, 20]], "date-time": "2009-02-20T19:45:47Z", "timestamp": 1235159147000}, "page": "209-211", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Lymphocytic Clusters in Peripheral Blood: An Atypical Morphologic Pattern of Chronic Lymphocytic Leukemia"], "prefix": "10.1159", "volume": "86", "author": [{"given": "Nicola", "family": "Bizzaro", "sequence": "first", "affiliation": []}, {"given": "Innocente", "family": "Piazza", "sequence": "additional", "affiliation": []}], "member": "127", "published-online": {"date-parts": [[2009, 2, 19]]}, "container-title": ["Acta Haematologica"], "language": "en", "link": [{"URL": "https://www.karger.com/Article/Pdf/204837", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://www.karger.com/Article/Pdf/204837", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 11, 6]], "date-time": "2017-11-06T23:50:30Z", "timestamp": 1510012230000}, "score": 29.58474, "issued": {"date-parts": [[1991]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2004, 7, 1]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1159/000204837", "archive": ["Portico"], "ISSN": ["0001-5792", "1421-9662"], "issn-type": [{"value": "0001-5792", "type": "print"}, {"value": "1421-9662", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:00:27Z", "timestamp": 1574521227513}, "reference-count": 53, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 12, 9]], "date-time": "2012-12-09T00:00:00Z", "timestamp": 1355011200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Genet"], "published-print": {"date-parts": [[2013, 1]]}, "DOI": "10.1038/ng.2495", "type": "journal-article", "created": {"date-parts": [[2012, 12, 9]], "date-time": "2012-12-09T20:07:21Z", "timestamp": 1355083641000}, "page": "18-24", "source": "Crossref", "is-referenced-by-count": 184, "title": ["Recurrent SETBP1 mutations in atypical chronic myeloid leukemia"], "prefix": "10.1038", "volume": "45", "author": [{"given": "Rocco", "family": "Piazza", "sequence": "first", "affiliation": []}, {"given": "Simona", "family": "Valletta", "sequence": "additional", "affiliation": []}, {"given": "Nils", "family": "Winkelmann", "sequence": "additional", "affiliation": []}, {"given": "Sara", "family": "Redaelli", "sequence": "additional", "affiliation": []}, {"given": "Roberta", "family": "Spinelli", "sequence": "additional", "affiliation": []}, {"given": "Alessandra", "family": "Pirola", "sequence": "additional", "affiliation": []}, {"given": "Laura", "family": "Antolini", "sequence": "additional", "affiliation": []}, {"given": "Luca", "family": "Mologni", "sequence": "additional", "affiliation": []}, {"given": "Carla", "family": "Donadoni", "sequence": "additional", "affiliation": []}, {"given": "Elli", "family": "Papaemmanuil", "sequence": "additional", "affiliation": []}, {"given": "Susanne", "family": "Schnittger", "sequence": "additional", "affiliation": []}, {"given": "Dong-Wook", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "Jacqueline", "family": "Boultwood", "sequence": "additional", "affiliation": []}, {"given": "Fabio", "family": "Rossi", "sequence": "additional", "affiliation": []}, {"given": "Giuseppe", "family": "Gaipa", "sequence": "additional", "affiliation": []}, {"given": "Greta P", "family": "De Martini", "sequence": "additional", "affiliation": []}, {"given": "Paola Francia", "family": "di Celle", "sequence": "additional", "affiliation": []}, {"given": "Hyun Gyung", "family": "Jang", "sequence": "additional", "affiliation": []}, {"given": "Valeria", "family": "Fantin", "sequence": "additional", "affiliation": []}, {"given": "Graham R", "family": "Bignell", "sequence": "additional", "affiliation": []}, {"given": "Vera", "family": "Magistroni", "sequence": "additional", "affiliation": []}, {"given": "Torsten", "family": "Haferlach", "sequence": "additional", "affiliation": []}, {"given": "Enrico Maria", "family": "Pogliani", "sequence": "additional", "affiliation": []}, {"given": "Peter J", "family": "Campbell", "sequence": "additional", "affiliation": []}, {"given": "Andrew J", "family": "Chase", "sequence": "additional", "affiliation": []}, {"given": "William J", "family": "Tapper", "sequence": "additional", "affiliation": []}, {"given": "Nicholas C P", "family": "Cross", "sequence": "additional", "affiliation": []}, {"given": "Carlo", "family": "Gambacorti-Passerini", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 12, 9]]}, "reference": [{"key": "BFng2495_CR1", "doi-asserted-by": "publisher", "first-page": "937", "DOI": "10.1182/blood-2009-03-209262", "volume": "114", "author": "JW Vardiman", "year": "2009", "unstructured": "Vardiman, J.W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937\u2013951 (2009).", "journal-title": "Blood"}, {"key": "BFng2495_CR2", "first-page": "1497", "volume": "132", "author": "PC Nowell", "year": "1960", "unstructured": "Nowell, P.C. & Hungerford, D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497\u20131497 (1960).", "journal-title": "Science"}, {"key": "BFng2495_CR3", "doi-asserted-by": "publisher", "first-page": "2915", "DOI": "10.1200/JCO.2001.19.11.2915", "volume": "19", "author": "R Kurzrock", "year": "2001", "unstructured": "Kurzrock, R. et al. BCR rearrangement\u2013negative chronic myelogenous leukemia revisited. J. Clin. Oncol. 19, 2915\u20132926 (2001).", "journal-title": "J. Clin. Oncol."}, {"key": "BFng2495_CR4", "doi-asserted-by": "publisher", "first-page": "1031", "DOI": "10.1056/NEJM200104053441401", "volume": "344", "author": "BJ Druker", "year": "2001", "unstructured": "Druker, B.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031\u20131037 (2001).", "journal-title": "N. Engl. J. Med."}, {"key": "BFng2495_CR5", "doi-asserted-by": "publisher", "first-page": "1028", "DOI": "10.1093/aje/kwq262", "volume": "172", "author": "P Rebora", "year": "2010", "unstructured": "Rebora, P. et al. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am. J. Epidemiol. 172, 1028\u20131033 (2010).", "journal-title": "Am. J. Epidemiol."}, {"key": "BFng2495_CR6", "doi-asserted-by": "publisher", "first-page": "553", "DOI": "10.1093/jnci/djr060", "volume": "103", "author": "C Gambacorti-Passerini", "year": "2011", "unstructured": "Gambacorti-Passerini, C. et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J. Natl. Cancer Inst. 103, 553\u2013561 (2011).", "journal-title": "J. Natl. Cancer Inst."}, {"key": "BFng2495_CR7", "doi-asserted-by": "publisher", "first-page": "302", "DOI": "10.1053/j.seminhematol.2010.07.001", "volume": "47", "author": "JM Goldman", "year": "2010", "unstructured": "Goldman, J.M. Chronic myeloid leukemia: a historical perspective. Semin. Hematol. 47, 302\u2013311 (2010).", "journal-title": "Semin. Hematol."}, {"key": "BFng2495_CR8", "doi-asserted-by": "publisher", "first-page": "2719", "DOI": "10.1056/NEJMoa0902542", "volume": "360", "author": "SP Shah", "year": "2009", "unstructured": "Shah, S.P. et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 360, 2719\u20132729 (2009).", "journal-title": "N. Engl. J. Med."}, {"key": "BFng2495_CR9", "doi-asserted-by": "publisher", "first-page": "2305", "DOI": "10.1056/NEJMoa1014209", "volume": "364", "author": "E Tiacci", "year": "2011", "unstructured": "Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305\u20132315 (2011).", "journal-title": "N. Engl. J. Med."}, {"key": "BFng2495_CR10", "doi-asserted-by": "publisher", "first-page": "1058", "DOI": "10.1056/NEJMoa0903840", "volume": "361", "author": "ER Mardis", "year": "2009", "unstructured": "Mardis, E.R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058\u20131066 (2009).", "journal-title": "N. Engl. J. Med."}, {"key": "BFng2495_CR11", "doi-asserted-by": "publisher", "first-page": "956", "DOI": "10.1056/NEJMe1200656", "volume": "366", "author": "DL Longo", "year": "2012", "unstructured": "Longo, D.L. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 366, 956\u2013957 (2012).", "journal-title": "N. Engl. J. Med."}, {"key": "BFng2495_CR12", "doi-asserted-by": "publisher", "first-page": "719", "DOI": "10.1038/nature07943", "volume": "458", "author": "MR Stratton", "year": "2009", "unstructured": "Stratton, M.R., Campbell, P.J. & Futreal, P.A. The cancer genome. Nature 458, 719\u2013724 (2009).", "journal-title": "Nature"}, {"key": "BFng2495_CR13", "doi-asserted-by": "publisher", "first-page": "1152", "DOI": "10.1056/NEJMe1200409", "volume": "366", "author": "LA Godley", "year": "2012", "unstructured": "Godley, L.A. Profiles in leukemia. N. Engl. J. Med. 366, 1152\u20131153 (2012).", "journal-title": "N. Engl. J. Med."}, {"key": "BFng2495_CR14", "doi-asserted-by": "publisher", "first-page": "722", "DOI": "10.1038/ng.621", "volume": "42", "author": "T Ernst", "year": "2010", "unstructured": "Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722\u2013726 (2010).", "journal-title": "Nat. Genet."}, {"key": "BFng2495_CR15", "doi-asserted-by": "publisher", "first-page": "1340", "DOI": "10.1046/j.1432-1327.2001.02000.x", "volume": "268", "author": "M Minakuchi", "year": "2001", "unstructured": "Minakuchi, M. et al. Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur. J. Biochem. 268, 1340\u20131351 (2001).", "journal-title": "Eur. J. Biochem."}, {"key": "BFng2495_CR16", "doi-asserted-by": "publisher", "first-page": "248", "DOI": "10.1038/nmeth0410-248", "volume": "7", "author": "IA Adzhubei", "year": "2010", "unstructured": "Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248\u2013249 (2010).", "journal-title": "Nat. Methods"}, {"key": "BFng2495_CR17", "doi-asserted-by": "publisher", "first-page": "1073", "DOI": "10.1038/nprot.2009.86", "volume": "4", "author": "P Kumar", "year": "2009", "unstructured": "Kumar, P., Henikoff, S. & Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073\u20131081 (2009).", "journal-title": "Nat. Protoc."}, {"key": "BFng2495_CR18", "doi-asserted-by": "publisher", "first-page": "e123", "DOI": "10.1093/nar/gks394", "volume": "40", "author": "R Piazza", "year": "2012", "unstructured": "Piazza, R. et al. FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. Nucleic Acids Res. 40, e123 (2012).", "journal-title": "Nucleic Acids Res."}, {"key": "BFng2495_CR19", "doi-asserted-by": "publisher", "first-page": "D242", "DOI": "10.1093/nar/gkr1064", "volume": "40", "author": "H Dinkel", "year": "2012", "unstructured": "Dinkel, H. et al. ELM\u2014the database of eukaryotic linear motifs. Nucleic Acids Res. 40, D242\u2013D251 (2012).", "journal-title": "Nucleic Acids Res."}, {"key": "BFng2495_CR20", "doi-asserted-by": "crossref", "first-page": "270", "DOI": "10.1101/gad.13.3.270", "volume": "13", "author": "JT Winston", "year": "1999", "unstructured": "Winston, J.T. et al. The SCF\u03b2-TRCP\u2013ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in I\u03baB\u03b1 and \u03b2-catenin and stimulates I\u03baB\u03b1 ubiquitination in vitro. Genes Dev. 13, 270\u2013283 (1999).", "journal-title": "Genes Dev."}, {"key": "BFng2495_CR21", "doi-asserted-by": "publisher", "first-page": "1634", "DOI": "10.3324/haematol.2009.014001", "volume": "94", "author": "A Reiter", "year": "2009", "unstructured": "Reiter, A., Invernizzi, R., Cross, N.C.P. & Cazzola, M. Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica 94, 1634\u20131638 (2009).", "journal-title": "Haematologica"}, {"key": "BFng2495_CR22", "doi-asserted-by": "publisher", "first-page": "615", "DOI": "10.1182/blood-2009-06-227363", "volume": "115", "author": "I Crist\u00f3bal", "year": "2010", "unstructured": "Crist\u00f3bal, I. et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 115, 615\u2013625 (2010).", "journal-title": "Blood"}, {"key": "BFng2495_CR23", "doi-asserted-by": "publisher", "first-page": "294", "DOI": "10.1111/j.1365-2141.2006.06410.x", "volume": "136", "author": "I Panagopoulos", "year": "2007", "unstructured": "Panagopoulos, I. et al. Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12). Br. J. Haematol. 136, 294\u2013296 (2007).", "journal-title": "Br. J. Haematol."}, {"key": "BFng2495_CR24", "doi-asserted-by": "publisher", "first-page": "395", "DOI": "10.1038/nature10933", "volume": "486", "author": "SP Shah", "year": "2012", "unstructured": "Shah, S.P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395\u2013399 (2012).", "journal-title": "Nature"}, {"key": "BFng2495_CR25", "doi-asserted-by": "publisher", "first-page": "496", "DOI": "10.1634/stemcells.2004-0265", "volume": "23", "author": "R Manfredini", "year": "2005", "unstructured": "Manfredini, R. et al. The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftment. Stem Cells 23, 496\u2013506 (2005).", "journal-title": "Stem Cells"}, {"key": "BFng2495_CR26", "doi-asserted-by": "publisher", "first-page": "6099", "DOI": "10.1182/blood-2011-10-388710", "volume": "119", "author": "K Oakley", "year": "2012", "unstructured": "Oakley, K. et al. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood 119, 6099\u20136108 (2012).", "journal-title": "Blood"}, {"key": "BFng2495_CR27", "doi-asserted-by": "publisher", "first-page": "355", "DOI": "10.1016/j.ccr.2005.10.015", "volume": "8", "author": "P Neviani", "year": "2005", "unstructured": "Neviani, P. et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8, 355\u2013368 (2005).", "journal-title": "Cancer Cell"}, {"key": "BFng2495_CR28", "doi-asserted-by": "publisher", "first-page": "34", "DOI": "10.1016/j.gde.2004.12.004", "volume": "15", "author": "V Janssens", "year": "2005", "unstructured": "Janssens, V., Goris, J. & Van Hoof, C. PP2A: the expected tumor suppressor. Curr. Opin. Genet. Dev. 15, 34\u201341 (2005).", "journal-title": "Curr. Opin. Genet. Dev."}, {"key": "BFng2495_CR29", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/S1359-6101(00)00031-9", "volume": "12", "author": "X Liu", "year": "2001", "unstructured": "Liu, X., Sun, Y., Weinberg, R.A. & Lodish, H.F. Ski/Sno and TGF-\u03b2 signaling. Cytokine Growth Factor Rev. 12, 1\u20138 (2001).", "journal-title": "Cytokine Growth Factor Rev."}, {"key": "BFng2495_CR30", "doi-asserted-by": "publisher", "first-page": "483", "DOI": "10.1038/ng.581", "volume": "42", "author": "A Hoischen", "year": "2010", "unstructured": "Hoischen, A. et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat. Genet. 42, 483\u2013485 (2010).", "journal-title": "Nat. Genet."}, {"key": "BFng2495_CR31", "first-page": "137", "volume": "157", "author": "GR Mundy", "year": "1991", "unstructured": "Mundy, G.R. The effects of Tgf-\u03b2 on bone. Ciba Found. Symp. 157, 137\u2013143 (1991).", "journal-title": "Ciba Found. Symp."}, {"key": "BFng2495_CR32", "doi-asserted-by": "publisher", "first-page": "1299", "DOI": "10.1002/ajmg.a.32277", "volume": "146A", "author": "AM Lehman", "year": "2008", "unstructured": "Lehman, A.M. et al. Schinzel-Giedion syndrome: report of splenopancreatic fusion and proposed diagnostic criteria. Am. J. Med. Genet. A 146A, 1299\u20131306 (2008).", "journal-title": "Am. J. Med. Genet. A"}, {"key": "BFng2495_CR33", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.18632/oncotarget.436", "volume": "3", "author": "NC Cross", "year": "2012", "unstructured": "Cross, N.C. Histone modification defects in developmental disorders and cancer. Oncotarget 3, 3\u20134 (2012).", "journal-title": "Oncotarget"}, {"key": "BFng2495_CR34", "doi-asserted-by": "publisher", "first-page": "1754", "DOI": "10.1093/bioinformatics/btp324", "volume": "25", "author": "H Li", "year": "2009", "unstructured": "Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).", "journal-title": "Bioinformatics"}, {"key": "BFng2495_CR35", "doi-asserted-by": "publisher", "first-page": "R86", "DOI": "10.1186/gb-2010-11-8-r86", "volume": "11", "author": "J Goecks", "year": "2010", "unstructured": "Goecks, J., Nekrutenko, A. & Taylor, J. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 11, R86 (2010).", "journal-title": "Genome Biol."}, {"key": "BFng2495_CR36", "unstructured": "Blankenberg, D. et al. Galaxy: a web-based genome analysis tool for experimentalists. Curr. Protoc. Mol. Biol. Chapter 19 Unit 19.10.1\u201321."}, {"key": "BFng2495_CR37", "doi-asserted-by": "publisher", "first-page": "1451", "DOI": "10.1101/gr.4086505", "volume": "15", "author": "B Giardine", "year": "2005", "unstructured": "Giardine, B. et al. Galaxy: a platform for interactive large-scale genome analysis. Genome Res. 15, 1451\u20131455 (2005).", "journal-title": "Genome Res."}, {"key": "BFng2495_CR38", "doi-asserted-by": "crossref", "first-page": "2078", "DOI": "10.1093/bioinformatics/btp352", "volume": "25", "author": "H Li", "year": "2009", "unstructured": "Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).", "journal-title": "Bioinformatics"}, {"key": "BFng2495_CR39", "doi-asserted-by": "publisher", "first-page": "1208", "DOI": "10.1182/blood-2011-07-367243", "volume": "119", "author": "J Score", "year": "2012", "unstructured": "Score, J. et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 119, 1208\u20131213 (2012).", "journal-title": "Blood"}, {"key": "BFng2495_CR40", "doi-asserted-by": "publisher", "first-page": "6182", "DOI": "10.1182/blood-2008-12-194548", "volume": "113", "author": "FH Grand", "year": "2009", "unstructured": "Grand, F.H. et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113, 6182\u20136192 (2009).", "journal-title": "Blood"}, {"key": "BFng2495_CR41", "doi-asserted-by": "publisher", "first-page": "1473", "DOI": "10.3324/haematol.2010.021808", "volume": "95", "author": "T Ernst", "year": "2010", "unstructured": "Ernst, T. et al. Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 95, 1473\u20131480 (2010).", "journal-title": "Haematologica"}, {"key": "BFng2495_CR42", "unstructured": "Randles, R.H. & Wolfe, D.A. Introduction to the Theory of Nonparametric Statistics (Wiley, 1979)."}, {"key": "BFng2495_CR43", "unstructured": "Marubini, E. & Valsecchi,, M.G. Analyzing Survival Data from Clinical Trials and Observational Studies (ed. Sons, J.W.) (Chichester, UK, 1995)."}, {"key": "BFng2495_CR44", "doi-asserted-by": "publisher", "first-page": "739", "DOI": "10.1038/nature08617", "volume": "462", "author": "L Dang", "year": "2009", "unstructured": "Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739\u2013744 (2009).", "journal-title": "Nature"}, {"key": "BFng2495_CR45", "first-page": "3780", "volume": "92", "author": "WS Pear", "year": "1998", "unstructured": "Pear, W.S. et al. Efficient and rapid induction of a chronic myelogenous leukemia\u2013like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780\u20133792 (1998).", "journal-title": "Blood"}, {"key": "BFng2495_CR46", "doi-asserted-by": "publisher", "first-page": "163", "DOI": "10.1093/jnci/91.2.163", "volume": "91", "author": "P le Coutre", "year": "1999", "unstructured": "le Coutre, P. et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91, 163\u2013168 (1999).", "journal-title": "J. Natl. Cancer Inst."}, {"key": "BFng2495_CR47", "doi-asserted-by": "publisher", "first-page": "1105", "DOI": "10.1093/bioinformatics/btp120", "volume": "25", "author": "C Trapnell", "year": "2009", "unstructured": "Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105\u20131111 (2009).", "journal-title": "Bioinformatics"}, {"key": "BFng2495_CR48", "doi-asserted-by": "publisher", "first-page": "R25", "DOI": "10.1186/gb-2009-10-3-r25", "volume": "10", "author": "B Langmead", "year": "2009", "unstructured": "Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).", "journal-title": "Genome Biol."}, {"key": "BFng2495_CR49", "doi-asserted-by": "publisher", "first-page": "24", "DOI": "10.1038/nbt.1754", "volume": "29", "author": "JT Robinson", "year": "2011", "unstructured": "Robinson, J.T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326 (2011).", "journal-title": "Nat. Biotechnol."}, {"key": "BFng2495_CR50", "doi-asserted-by": "publisher", "first-page": "2", "DOI": "10.1186/1751-0473-6-2", "volume": "6", "author": "G Xu", "year": "2011", "unstructured": "Xu, G. et al. SAMMate: a GUI tool for processing short read alignments in SAM/BAM format. Source Code Biol. Med. 6, 2 (2011).", "journal-title": "Source Code Biol. Med."}, {"key": "BFng2495_CR51", "doi-asserted-by": "publisher", "first-page": "621", "DOI": "10.1038/nmeth.1226", "volume": "5", "author": "A Mortazavi", "year": "2008", "unstructured": "Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621\u2013628 (2008).", "journal-title": "Nat. Methods"}, {"key": "BFng2495_CR52", "doi-asserted-by": "crossref", "first-page": "R106", "DOI": "10.1186/gb-2010-11-10-r106", "volume": "11", "author": "S Anders", "year": "2010", "unstructured": "Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).", "journal-title": "Genome Biol."}, {"key": "BFng2495_CR53", "doi-asserted-by": "publisher", "first-page": "2213", "DOI": "10.1101/gr.124321.111", "volume": "21", "author": "S Tarazona", "year": "2011", "unstructured": "Tarazona, S., Garcia-Alcalde, F., Dopazo, J., Ferrer, A. & Conesa, A. Differential expression in RNA-seq: a matter of depth. Genome Res. 21, 2213\u20132223 (2011).", "journal-title": "Genome Res."}], "container-title": ["Nature Genetics"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/ng.2495.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/ng.2495", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/ng.2495.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 12]], "date-time": "2019-10-12T07:41:35Z", "timestamp": 1570866095000}, "score": 29.433218, "issued": {"date-parts": [[2012, 12, 9]]}, "references-count": 53, "journal-issue": {"published-print": {"date-parts": [[2013, 1]]}, "issue": "1"}, "alternative-id": ["BFng2495"], "URL": "http://dx.doi.org/10.1038/ng.2495", "relation": {"cites": []}, "ISSN": ["1061-4036", "1546-1718"], "issn-type": [{"value": "1061-4036", "type": "print"}, {"value": "1546-1718", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:59:45Z", "timestamp": 1574539185683}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 4, 15]]}, "DOI": "10.1158/1538-7445.am2013-2993", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T23:08:53Z", "timestamp": 1408057733000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 2993: Patterns of recurrent mutations in SETBP1 mutated and wild-type atypical Chronic Myeloid Leukemia patients."], "prefix": "10.1158", "author": [{"given": "Sara", "family": "Redaelli", "sequence": "first", "affiliation": []}, {"given": "Simona", "family": "Valletta", "sequence": "additional", "affiliation": []}, {"given": "Rocco", "family": "Piazza", "sequence": "additional", "affiliation": []}, {"given": "Nils", "family": "Winkelmann", "sequence": "additional", "affiliation": []}, {"given": "Roberta", "family": "Spinelli", "sequence": "additional", "affiliation": []}, {"given": "Alessandra", "family": "Pirola", "sequence": "additional", "affiliation": []}, {"given": "Laura", "family": "Antolini", "sequence": "additional", "affiliation": []}, {"given": "Luca", "family": "Mologni", "sequence": "additional", "affiliation": []}, {"given": "Carla", "family": "Donadoni", "sequence": "additional", "affiliation": []}, {"given": "Elli", "family": "Papaemmanuil", "sequence": "additional", "affiliation": []}, {"given": "Susanne", "family": "Schnittger", "sequence": "additional", "affiliation": []}, {"given": "Kim", "family": "Dong-Wook", "sequence": "additional", "affiliation": []}, {"given": "Jacqueline", "family": "Boultwood", "sequence": "additional", "affiliation": []}, {"given": "Fabio", "family": "Rossi", "sequence": "additional", "affiliation": []}, {"given": "Giuseppe", "family": "Gaipa", "sequence": "additional", "affiliation": []}, {"given": "Greta", "family": "De Martini", "sequence": "additional", "affiliation": []}, {"given": "Paola", "family": "Francia di Celle", "sequence": "additional", "affiliation": []}, {"given": "Hyun Gyung", "family": "Jang", "sequence": "additional", "affiliation": []}, {"given": "Valeria", "family": "Fantin", "sequence": "additional", "affiliation": []}, {"given": "Graham R.", "family": "Bignell", "sequence": "additional", "affiliation": []}, {"given": "Vera", "family": "Magistroni", "sequence": "additional", "affiliation": []}, {"given": "Torsten", "family": "Haferlach", "sequence": "additional", "affiliation": []}, {"given": "Enrico Maria", "family": "Pogliani", "sequence": "additional", "affiliation": []}, {"given": "Peter", "family": "Campbell", "sequence": "additional", "affiliation": []}, {"given": "Andrew J.", "family": "Chase", "sequence": "additional", "affiliation": []}, {"given": "William J.", "family": "Tapper", "sequence": "additional", "affiliation": []}, {"given": "Nick C.P.", "family": "Cross", "sequence": "additional", "affiliation": []}, {"given": "Carlo", "family": "Gambacorti Passerini", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 18]]}, "event": {"name": "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC"}, "container-title": ["Molecular and Cellular Biology"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2013-2993", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T20:09:55Z", "timestamp": 1558210195000}, "score": 29.433218, "issued": {"date-parts": [[2013, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2013-2993"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2013-2993"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T05:38:48Z", "timestamp": 1575178728246}, "reference-count": 12, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2013, 2, 5]], "date-time": "2013-02-05T00:00:00Z", "timestamp": 1360022400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[2013, 6]]}, "DOI": "10.1038/leu.2013.35", "type": "journal-article", "created": {"date-parts": [[2013, 2, 5]], "date-time": "2013-02-05T14:04:48Z", "timestamp": 1360073088000}, "page": "1401-1403", "source": "Crossref", "is-referenced-by-count": 64, "title": ["SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias"], "prefix": "10.1038", "volume": "27", "author": [{"given": "F", "family": "Damm", "sequence": "first", "affiliation": []}, {"given": "R", "family": "Itzykson", "sequence": "additional", "affiliation": []}, {"given": "O", "family": "Kosmider", "sequence": "additional", "affiliation": []}, {"given": "N", "family": "Droin", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Renneville", "sequence": "additional", "affiliation": []}, {"given": "V", "family": "Chesnais", "sequence": "additional", "affiliation": []}, {"given": "V", "family": "Gelsi-Boyer", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "de Botton", "sequence": "additional", "affiliation": []}, {"given": "N", "family": "Vey", "sequence": "additional", "affiliation": []}, {"given": "C", "family": "Preudhomme", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Clavert", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Delabesse", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Park", "sequence": "additional", "affiliation": []}, {"given": "D", "family": "Birnbaum", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Fontenay", "sequence": "additional", "affiliation": []}, {"given": "O A", "family": "Bernard", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Solary", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2013, 2, 5]]}, "reference": [{"key": "BFleu201335_CR1", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1038/ng.2495", "volume": "45", "author": "R Piazza", "year": "2012", "unstructured": "Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2012; 45: 18\u201324.", "journal-title": "Nat Genet"}, {"key": "BFleu201335_CR2", "doi-asserted-by": "publisher", "first-page": "483", "DOI": "10.1038/ng.581", "volume": "42", "author": "A Hoischen", "year": "2010", "unstructured": "Hoischen A, van Bon BW, Gilissen C, Arts P, van Lier B, Steehouwer M et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet 2010; 42: 483\u2013485.", "journal-title": "Nat Genet"}, {"key": "BFleu201335_CR3", "doi-asserted-by": "publisher", "first-page": "294", "DOI": "10.1111/j.1365-2141.2006.06410.x", "volume": "136", "author": "I Panagopoulos", "year": "2007", "unstructured": "Panagopoulos I, Kerndrup G, Carlsen N, Strombeck B, Isaksson M, Johansson B . Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12). Br J Haematol 2007; 136: 294\u2013296.", "journal-title": "Br J Haematol"}, {"key": "BFleu201335_CR4", "doi-asserted-by": "publisher", "first-page": "615", "DOI": "10.1182/blood-2009-06-227363", "volume": "115", "author": "I Cristobal", "year": "2010", "unstructured": "Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010; 115: 615\u2013625.", "journal-title": "Blood"}, {"key": "BFleu201335_CR5", "doi-asserted-by": "publisher", "first-page": "6099", "DOI": "10.1182/blood-2011-10-388710", "volume": "119", "author": "K Oakley", "year": "2012", "unstructured": "Oakley K, Han Y, Vishwakarma BA, Chu S, Bhatia R, Gudmundsson KO et al. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood 2012; 119: 6099\u20136108.", "journal-title": "Blood"}, {"key": "BFleu201335_CR6", "doi-asserted-by": "publisher", "first-page": "1059", "DOI": "10.3324/haematol.2011.040840", "volume": "96", "author": "O Kosmider", "year": "2011", "unstructured": "Kosmider O, Delabesse E, Mas VM, Cornillet-Lefebvre P, Blanchet O, Delmer A et al. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica 2011; 96: 1059\u20131063.", "journal-title": "Haematologica"}, {"key": "BFleu201335_CR7", "doi-asserted-by": "publisher", "first-page": "3211", "DOI": "10.1182/blood-2011-12-400994", "volume": "119", "author": "F Damm", "year": "2012", "unstructured": "Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119: 3211\u20133218.", "journal-title": "Blood"}, {"key": "BFleu201335_CR8", "unstructured": "Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V . A prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; (in press).", "DOI": "10.1200/JCO.2012.47.3314", "doi-asserted-by": "crossref"}, {"key": "BFleu201335_CR9", "unstructured": "Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013; e-pub ahead of print 14 January 2013.", "DOI": "10.1182/blood-2012-06-440347", "doi-asserted-by": "crossref"}, {"key": "BFleu201335_CR10", "doi-asserted-by": "publisher", "first-page": "453", "DOI": "10.1182/blood-2009-07-235358", "volume": "115", "author": "H Dohner", "year": "2010", "unstructured": "Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453\u2013474.", "journal-title": "Blood"}, {"key": "BFleu201335_CR11", "doi-asserted-by": "publisher", "first-page": "1154", "DOI": "10.1056/NEJMc1108665", "volume": "365", "author": "F Damm", "year": "2011", "unstructured": "Damm F, Fontenay M, Bernard OA . Point mutations in myelodysplastic syndromes. N Engl J Med 2011; 365: 1154\u20131155.", "journal-title": "N Engl J Med"}, {"key": "BFleu201335_CR12", "doi-asserted-by": "publisher", "first-page": "1090", "DOI": "10.1056/NEJMoa1106968", "volume": "366", "author": "MJ Walter", "year": "2012", "unstructured": "Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090\u20131098.", "journal-title": "N Engl J Med"}], "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/leu201335.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/leu201335", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/leu201335.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 13]], "date-time": "2019-05-13T22:31:30Z", "timestamp": 1557786690000}, "score": 28.966808, "issued": {"date-parts": [[2013, 2, 5]]}, "references-count": 12, "journal-issue": {"published-print": {"date-parts": [[2013, 6]]}, "issue": "6"}, "alternative-id": ["BFleu201335"], "URL": "http://dx.doi.org/10.1038/leu.2013.35", "relation": {"cites": []}, "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}], "subject": ["Anesthesiology and Pain Medicine", "Cancer Research", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T17:26:19Z", "timestamp": 1575221179746}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 5, 1]], "date-time": "2013-05-01T00:00:00Z", "timestamp": 1367366400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia Research"], "published-print": {"date-parts": [[2013, 5]]}, "DOI": "10.1016/s0145-2126(13)70053-5", "type": "journal-article", "created": {"date-parts": [[2013, 5, 9]], "date-time": "2013-05-09T07:35:54Z", "timestamp": 1368084954000}, "page": "S24", "source": "Crossref", "is-referenced-by-count": 0, "title": ["P-004 SETBP1 mutations in 658 patients with myeldodysplastic syndromes, chronic myelomonocytic leukemia and secondary AML"], "prefix": "10.1016", "volume": "37", "author": [{"given": "F.", "family": "Damm", "sequence": "first", "affiliation": []}, {"given": "R.", "family": "Itzykson", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Kosmider", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Droin", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Clavert", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Preudhomme", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Birnbaum", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Fontenay", "sequence": "additional", "affiliation": []}, {"given": "O.A.", "family": "Bernard", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Solary", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Leukemia Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0145212613700535?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0145212613700535?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 16]], "date-time": "2018-10-16T04:26:57Z", "timestamp": 1539664017000}, "score": 28.601875, "issued": {"date-parts": [[2013, 5]]}, "references-count": 0, "alternative-id": ["S0145212613700535"], "URL": "http://dx.doi.org/10.1016/s0145-2126(13)70053-5", "ISSN": ["0145-2126"], "issn-type": [{"value": "0145-2126", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T11:31:35Z", "timestamp": 1575459095595}, "reference-count": 10, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "start": {"date-parts": [[2019, 6, 20]], "date-time": "2019-06-20T00:00:00Z", "timestamp": 1560988800000}, "delay-in-days": 0, "content-version": "vor"}, {"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2019, 6, 20]], "date-time": "2019-06-20T00:00:00Z", "timestamp": 1560988800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["onlinelibrary.wiley.com"], "crossmark-restriction": true}, "short-container-title": ["Hematological Oncology"], "published-print": {"date-parts": [[2019, 10]]}, "DOI": "10.1002/hon.2638", "type": "journal-article", "created": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T12:14:45Z", "timestamp": 1558181685000}, "page": "505-507", "update-policy": "http://dx.doi.org/10.1002/crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL)"], "prefix": "10.1002", "volume": "37", "author": [{"ORCID": "http://orcid.org/0000-0001-6664-2290", "authenticated-orcid": false, "given": "Ramona", "family": "Cassin", "sequence": "first", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Veronica", "family": "Mattiello", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Michela", "family": "Viltadi", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Deborah", "family": "D'Aliberti", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Rocco", "family": "Piazza", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Carlo", "family": "Gambacorti\u2010Passerini", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Umberto", "family": "Gianelli", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Antonino", "family": "Neri", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Agostino", "family": "Cortelezzi", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}, {"given": "Gianluigi", "family": "Reda", "sequence": "additional", "affiliation": [{"name": "Hematology UnitIRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milan Italy"}]}], "member": "311", "published-online": {"date-parts": [[2019, 6, 20]]}, "reference": [{"key": "e_1_2_2_2_1", "DOI": "10.1182/blood-2016-03-643544", "doi-asserted-by": "publisher"}, {"issue": "11", "key": "e_1_2_2_3_1", "first-page": "1566", "article-title": "Identification of risk factors in atypical chronic myeloid leukemia", "volume": "91", "author": "Breccia M", "year": "2006", "journal-title": "Haematologica"}, {"key": "e_1_2_2_4_1", "DOI": "10.1016/j.leukres.2013.01.004", "doi-asserted-by": "publisher"}, {"key": "e_1_2_2_5_1", "DOI": "10.1016/j.lrr.2014.07.002", "doi-asserted-by": "publisher"}, {"key": "e_1_2_2_6_1", "DOI": "10.1002/cncr.10832", "doi-asserted-by": "publisher"}, {"issue": "01", "key": "e_1_2_2_7_1", "first-page": "114", "article-title": "The first case of decitabine successfully in treatment of atypical chronic myeloid leukemia with CEPBPA double mutation", "volume": "2", "author": "Mao L", "year": "2013", "journal-title": "Chemotherapy"}, {"key": "e_1_2_2_8_1", "DOI": "10.3109/10428194.2014.986477", "doi-asserted-by": "publisher"}, {"key": "e_1_2_2_9_1", "DOI": "10.1177/1078155215605662", "doi-asserted-by": "publisher"}, {"key": "e_1_2_2_10_1", "DOI": "10.3892/ol.2015.3977", "doi-asserted-by": "publisher"}, {"key": "e_1_2_2_11_1", "DOI": "10.1111/j.1365-2141.2010.08213.x", "doi-asserted-by": "publisher"}], "container-title": ["Hematological Oncology"], "language": "en", "link": [{"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2638", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full-xml/10.1002/hon.2638", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2638", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 29]], "date-time": "2019-10-29T11:48:33Z", "timestamp": 1572349713000}, "score": 28.429712, "issued": {"date-parts": [[2019, 6, 20]]}, "references-count": 10, "journal-issue": {"published-online": {"date-parts": [[2019, 7, 15]]}, "published-print": {"date-parts": [[2019, 10]]}, "issue": "4"}, "alternative-id": ["10.1002/hon.2638"], "URL": "http://dx.doi.org/10.1002/hon.2638", "archive": ["Portico"], "relation": {"has-review": [{"id-type": "doi", "id": "10.1002/HON.2638/v1/decision1", "asserted-by": "object"}, {"id-type": "doi", "id": "10.1002/HON.2638/v1/review1", "asserted-by": "object"}, {"id-type": "doi", "id": "10.1002/HON.2638/v2/response1", "asserted-by": "object"}, {"id-type": "doi", "id": "10.1002/HON.2638/v2/decision1", "asserted-by": "object"}, {"id-type": "doi", "id": "10.1002/HON.2638/v2/review1", "asserted-by": "object"}], "cites": []}, "ISSN": ["0278-0232", "1099-1069"], "issn-type": [{"value": "0278-0232", "type": "print"}, {"value": "1099-1069", "type": "electronic"}], "subject": ["Cancer Research", "Oncology", "Hematology", "General Medicine"], "assertion": [{"value": "2019-01-23", "order": 0, "name": "received", "label": "Received", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-05-12", "order": 1, "name": "accepted", "label": "Accepted", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-06-20", "order": 2, "name": "published", "label": "Published", "group": {"name": "publication_history", "label": "Publication History"}}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T14:09:52Z", "timestamp": 1574518192567}, "reference-count": 11, "publisher": "Wiley", "issue": "7", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1540, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Am. J. Hematol."], "published-print": {"date-parts": [[2011, 7]]}, "DOI": "10.1002/ajh.22084", "type": "journal-article", "created": {"date-parts": [[2011, 6, 14]], "date-time": "2011-06-14T19:40:36Z", "timestamp": 1308080436000}, "page": "531-532", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Choosing the right TKI for chronic myeloid leukemia: When the truth lies in \u201clong-term\u201d safety and efficacy"], "prefix": "10.1002", "volume": "86", "author": [{"given": "Carlo", "family": "Gambacorti-Passerini", "sequence": "first", "affiliation": []}, {"given": "Rocco", "family": "Piazza", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 6, 14]]}, "reference": [{"key": "10.1002/ajh.22084-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "129", "DOI": "10.1016/j.ccr.2005.01.007", "article-title": "Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl", "volume": "7", "author": "Weisberg", "year": "2005", "journal-title": "Cancer Cell"}, {"key": "10.1002/ajh.22084-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "469", "DOI": "10.1200/JCO.2008.19.8853", "article-title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants", "volume": "27", "author": "Redaelli", "year": "2009", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ajh.22084-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "611", "DOI": "10.2217/14796694.4.5.611", "article-title": "Nilotinib: A phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases", "volume": "4", "author": "Quint\u00e1s-Cardama", "year": "2008", "journal-title": "Future Oncol"}, {"key": "10.1002/ajh.22084-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "1834", "DOI": "10.1182/blood-2007-04-083196", "article-title": "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia", "volume": "111", "author": "le Coutre", "year": "2008", "journal-title": "Blood"}, {"key": "10.1002/ajh.22084-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "3540", "DOI": "10.1182/blood-2007-03-080689", "article-title": "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance", "volume": "110", "author": "Kantarjian", "year": "2007", "journal-title": "Blood"}, {"key": "10.1002/ajh.22084-BIB6|cit6", "author": "Aichberger", "year": "2011", "article-title": "Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML", "journal-title": "Am J Hematol", "DOI": "10.1002/ajh.22037", "doi-asserted-by": "crossref"}, {"key": "10.1002/ajh.22084-BIB7|cit7", "author": "Tefferi", "year": "2011", "article-title": "Nilotinib treatment associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia", "journal-title": "Am J Hematol", "DOI": "10.1002/ajh.22051", "doi-asserted-by": "crossref"}, {"key": "10.1002/ajh.22084-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "553", "DOI": "10.1093/jnci/djr060", "article-title": "Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib", "volume": "103", "author": "Gambacorti-Passerini", "year": "2011", "journal-title": "J Natl Cancer Inst"}, {"key": "10.1002/ajh.22084-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "4653", "DOI": "10.1200/JCO.2004.04.217", "article-title": "Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment", "volume": "22", "author": "Breccia", "year": "2004", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ajh.22084-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "317", "DOI": "10.3324/haematol.11680", "article-title": "Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib", "volume": "93", "author": "Franceschino", "year": "2008", "journal-title": "Haematologica"}, {"key": "10.1002/ajh.22084-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "2251", "DOI": "10.1056/NEJMoa0912614", "article-title": "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia", "volume": "362", "author": "Saglio", "year": "2010", "journal-title": "N Engl J Med"}], "container-title": ["American Journal of Hematology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fajh.22084", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.22084", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 1]], "date-time": "2018-08-01T23:16:34Z", "timestamp": 1533165394000}, "score": 28.418762, "issued": {"date-parts": [[2011, 6, 14]]}, "references-count": 11, "journal-issue": {"published-print": {"date-parts": [[2011, 7]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1002/ajh.22084", "relation": {"cites": []}, "ISSN": ["0361-8609"], "issn-type": [{"value": "0361-8609", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T01:18:15Z", "timestamp": 1574558295027}, "reference-count": 68, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 281, "content-version": "tdm"}], "funder": [{"DOI": "10.13039/501100005010", "name": "Associazione Italiana per la Ricerca sul Cancro", "doi-asserted-by": "crossref", "award": ["AIRC 2013 IG-14249"]}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Am. J. Hematol."], "published-print": {"date-parts": [[2015, 2]]}, "DOI": "10.1002/ajh.23887", "type": "journal-article", "created": {"date-parts": [[2014, 11, 5]], "date-time": "2014-11-05T07:00:49Z", "timestamp": 1415170849000}, "page": "156-161", "source": "Crossref", "is-referenced-by-count": 13, "title": ["How I treat newly diagnosed chronic myeloid leukemia in 2015"], "prefix": "10.1002", "volume": "90", "author": [{"given": "Carlo", "family": "Gambacorti-Passerini", "sequence": "first", "affiliation": [{"name": "Department of Health Sciences; University of Milano-Bicocca, Section of Hematology, San Gerardo Hospital; Monza Italy"}]}, {"given": "Rocco", "family": "Piazza", "sequence": "additional", "affiliation": [{"name": "Department of Health Sciences; University of Milano-Bicocca, Section of Hematology, San Gerardo Hospital; Monza Italy"}]}], "member": "311", "published-online": {"date-parts": [[2014, 11, 24]]}, "reference": [{"key": "10.1002/ajh.23887-BIB0001|ajh23887-cit-0001", "doi-asserted-by": "crossref", "first-page": "1031", "DOI": "10.1056/NEJM200104053441401", "article-title": "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", "volume": "344", "author": "Druker", "year": "2001", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0002|ajh23887-cit-0002", "doi-asserted-by": "crossref", "first-page": "645", "DOI": "10.1056/NEJMoa011573", "article-title": "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", "volume": "346", "author": "Kantarjian", "year": "2002", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0003|ajh23887-cit-0003", "doi-asserted-by": "crossref", "first-page": "2408", "DOI": "10.1056/NEJMoa062867", "article-title": "Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia", "volume": "355", "author": "Druker", "year": "2006", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0004|ajh23887-cit-0004", "doi-asserted-by": "crossref", "first-page": "561", "DOI": "10.1038/nm0596-561", "article-title": "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", "volume": "2", "author": "Druker", "year": "1996", "journal-title": "Nat Med"}, {"key": "10.1002/ajh.23887-BIB0005|ajh23887-cit-0005", "doi-asserted-by": "crossref", "first-page": "380", "DOI": "10.1006/bcmd.1997.0155", "article-title": "Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis", "volume": "23", "author": "Gambacorti-Passerini", "year": "1997", "journal-title": "Blood Cells Mol Dis"}, {"key": "10.1002/ajh.23887-BIB0006|ajh23887-cit-0006", "first-page": "3691", "article-title": "The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells", "volume": "90", "author": "Deininger", "year": "1997", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0007|ajh23887-cit-0007", "doi-asserted-by": "crossref", "first-page": "553", "DOI": "10.1093/jnci/djr060", "article-title": "Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib", "volume": "103", "author": "Gambacorti-Passerini", "year": "2011", "journal-title": "J Natl Cancer Inst"}, {"key": "10.1002/ajh.23887-BIB0008|ajh23887-cit-0008", "doi-asserted-by": "crossref", "first-page": "E184", "DOI": "10.1002/ajh.23804", "article-title": "First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis", "volume": "89", "author": "Vigano", "year": "2014", "journal-title": "Am J Hematol"}, {"key": "10.1002/ajh.23887-BIB0009|ajh23887-cit-0009", "doi-asserted-by": "crossref", "first-page": "527", "DOI": "10.1093/jnci/djr073", "article-title": "Imatinib for Chronic Myeloid Leukemia: The impact of its effectveness and long-term side effects", "volume": "103", "author": "Smith", "year": "2011", "journal-title": "J Natl Cancer Inst"}, {"key": "10.1002/ajh.23887-BIB0010|ajh23887-cit-0010", "doi-asserted-by": "crossref", "first-page": "1028", "DOI": "10.1093/aje/kwq262", "article-title": "Are chronic myeloid leukemia patients more at risk for second malignancies?. A population-based study", "volume": "172", "author": "Rebora", "year": "2010", "journal-title": "Am J Epidemiol"}, {"key": "10.1002/ajh.23887-BIB0011|ajh23887-cit-0011", "doi-asserted-by": "crossref", "first-page": "2514", "DOI": "10.1200/JCO.2011.34.7146", "article-title": "Success story of targeted therapy in chronic myeloid leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 2008", "volume": "29", "author": "Bjorkholm", "year": "2011", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ajh.23887-BIB0012|ajh23887-cit-0012", "doi-asserted-by": "crossref", "first-page": "2531", "DOI": "10.1056/NEJMoa055229", "article-title": "Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias", "volume": "354", "author": "Talpaz", "year": "2006", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0013|ajh23887-cit-0013", "doi-asserted-by": "crossref", "first-page": "2542", "DOI": "10.1056/NEJMoa055104", "article-title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL", "volume": "354", "author": "Kantarjian", "year": "2006", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0014|ajh23887-cit-0014", "doi-asserted-by": "crossref", "first-page": "4567", "DOI": "10.1182/blood-2011-05-355594", "article-title": "Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib", "volume": "118", "author": "Cortes", "year": "2011", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0015|ajh23887-cit-0015", "doi-asserted-by": "crossref", "first-page": "1783", "DOI": "10.1056/NEJMoa1306494", "article-title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias", "volume": "369", "author": "Cortes", "year": "2013", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0016|ajh23887-cit-0016", "doi-asserted-by": "crossref", "first-page": "1191", "DOI": "10.3324/haematol.2013.096776", "article-title": "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors", "volume": "99", "author": "Kim", "year": "2014", "journal-title": "Haematologica"}, {"key": "10.1002/ajh.23887-BIB0017|ajh23887-cit-0017", "doi-asserted-by": "crossref", "first-page": "2260", "DOI": "10.1056/NEJMoa1002315", "article-title": "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia", "volume": "362", "author": "Kantarjian", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0018|ajh23887-cit-0018", "doi-asserted-by": "crossref", "first-page": "2251", "DOI": "10.1056/NEJMoa0912614", "article-title": "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia", "volume": "362", "author": "Saglio", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0019|ajh23887-cit-0019", "doi-asserted-by": "crossref", "first-page": "994", "DOI": "10.1056/NEJMoa022457", "article-title": "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", "volume": "348", "author": "O'Brien", "year": "2003", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0020|ajh23887-cit-0020", "first-page": "935", "article-title": "Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia", "volume": "8", "author": "Cohen", "year": "2002", "journal-title": "Clin Cancer Res"}, {"key": "10.1002/ajh.23887-BIB0021|ajh23887-cit-0021", "doi-asserted-by": "crossref", "first-page": "1928", "DOI": "10.1182/blood.V99.6.1928", "article-title": "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study", "volume": "99", "author": "Talpaz", "year": "2002", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0022|ajh23887-cit-0022", "doi-asserted-by": "crossref", "first-page": "3530", "DOI": "10.1182/blood.V99.10.3530", "article-title": "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study", "volume": "99", "author": "Sawyers", "year": "2002", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0023|ajh23887-cit-0023", "doi-asserted-by": "crossref", "first-page": "1039", "DOI": "10.1182/blood-2007-07-103523", "article-title": "Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment", "volume": "111", "author": "Hochhaus", "year": "2008", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0024|ajh23887-cit-0024", "doi-asserted-by": "crossref", "first-page": "3358", "DOI": "10.1200/JCO.2007.15.8154", "article-title": "Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis", "volume": "26", "author": "Lavallade", "year": "2008", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ajh.23887-BIB0025|ajh23887-cit-0025", "doi-asserted-by": "crossref", "first-page": "318", "DOI": "10.1002/ajh.21942", "article-title": "Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?", "volume": "86", "author": "Zackova", "year": "2011", "journal-title": "Am J Hematol"}, {"key": "10.1002/ajh.23887-BIB0026|ajh23887-cit-0026", "doi-asserted-by": "crossref", "first-page": "415", "DOI": "10.1200/JCO.2013.49.9020", "article-title": "Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-study IV", "volume": "32", "author": "Hehlmann", "year": "2014", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ajh.23887-BIB0027|ajh23887-cit-0027", "doi-asserted-by": "crossref", "first-page": "5591", "DOI": "10.1182/blood-2010-12-324228", "article-title": "Frontline imatinib treatment of chronic myeloid leukemia: No impact of age on outcome, a survey by the GIMEMA CML Working Party", "volume": "117", "author": "Gugliotta", "year": "2011", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0028|ajh23887-cit-0028", "doi-asserted-by": "crossref", "first-page": "2511", "DOI": "10.1056/NEJMoa1004095", "article-title": "Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia", "volume": "363", "author": "Preudhomme", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0029|ajh23887-cit-0029", "doi-asserted-by": "crossref", "first-page": "1963", "DOI": "10.1038/leu.2008.225", "article-title": "A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials", "volume": "22", "author": "Lucas", "year": "2008", "journal-title": "Leukemia"}, {"key": "10.1002/ajh.23887-BIB0030|ajh23887-cit-0030", "doi-asserted-by": "crossref", "first-page": "838", "DOI": "10.1002/ajh.23501", "article-title": "Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: A retrospective study on 91 unselected patients", "volume": "88", "author": "Cerrano", "year": "2013", "journal-title": "Am J Hematol"}, {"key": "10.1002/ajh.23887-BIB0031|ajh23887-cit-0031", "doi-asserted-by": "crossref", "first-page": "4554", "DOI": "10.1182/blood-2011-04-347575", "article-title": "Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population", "volume": "118", "author": "Efficace", "year": "2011", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0032|ajh23887-cit-0032", "doi-asserted-by": "crossref", "first-page": "1173", "DOI": "10.1016/j.leukres.2014.06.020", "article-title": "Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival", "volume": "38", "author": "Breccia", "year": "2014", "journal-title": "Leuk Res"}, {"key": "10.1002/ajh.23887-BIB0033|ajh23887-cit-0033", "doi-asserted-by": "crossref", "first-page": "908", "DOI": "10.1038/nm1446", "article-title": "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate", "volume": "12", "author": "Kerkela", "year": "2006", "journal-title": "Nat Med"}, {"key": "10.1002/ajh.23887-BIB0034|ajh23887-cit-0034", "doi-asserted-by": "crossref", "first-page": "13", "DOI": "10.1038/nm0107-13b", "article-title": "In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019", "volume": "13", "author": "Gambacorti-Passerini", "year": "2007", "journal-title": "Nat Med"}, {"key": "10.1002/ajh.23887-BIB0035|ajh23887-cit-0035", "doi-asserted-by": "crossref", "first-page": "36", "DOI": "10.1016/j.leukres.2010.09.021", "article-title": "Cardiotoxicity of imatinib: At the heart of the problem", "volume": "35", "author": "Tiribelli", "year": "2011", "journal-title": "Leuk Res"}, {"key": "10.1002/ajh.23887-BIB0036|ajh23887-cit-0036", "doi-asserted-by": "crossref", "first-page": "4016", "DOI": "10.1182/blood-2006-11-057521", "article-title": "Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells", "volume": "109", "author": "Jorgensen", "year": "2007", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0037|ajh23887-cit-0037", "doi-asserted-by": "crossref", "first-page": "396", "DOI": "10.1172/JCI35721", "article-title": "Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity", "volume": "121", "author": "Corbin", "year": "2011", "journal-title": "J Clin Invest"}, {"key": "10.1002/ajh.23887-BIB0038|ajh23887-cit-0038", "doi-asserted-by": "crossref", "first-page": "1029", "DOI": "10.1016/S1470-2045(10)70233-3", "article-title": "Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial", "volume": "11", "author": "Mahon", "year": "2010", "journal-title": "Lancet Oncol"}, {"key": "10.1002/ajh.23887-BIB0039|ajh23887-cit-0039", "doi-asserted-by": "crossref", "first-page": "515", "DOI": "10.1182/blood-2013-02-483750", "article-title": "Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study", "volume": "122", "author": "Ross", "year": "2013", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0040|ajh23887-cit-0040", "author": "Benjamini", "year": "2013", "article-title": "Patient-driven discontinuation of tyrosine kinase inhibitors: Single institution experience", "journal-title": "Leuk Lymphoma"}, {"key": "10.1002/ajh.23887-BIB0041|ajh23887-cit-0041", "doi-asserted-by": "crossref", "first-page": "22", "DOI": "10.1016/j.canlet.2014.01.033", "article-title": "Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia", "volume": "347", "author": "Breccia", "year": "2014", "journal-title": "Cancer Lett"}, {"key": "10.1002/ajh.23887-BIB0042|ajh23887-cit-0042", "author": "Mori", "first-page": "283", "year": "2014", "volume-title": "Age and Digital-PCR Analysis Predict Relapses of CML Patients Following Programmed Imatinib Interruption in Q-RT-PCR Negatice Chronic Myeloid Leukemia Patients"}, {"key": "10.1002/ajh.23887-BIB0043|ajh23887-cit-0043", "doi-asserted-by": "crossref", "first-page": "494", "DOI": "10.1182/blood-2013-06-511592", "article-title": "Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)", "volume": "123", "author": "Jabbour", "year": "2014", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0044|ajh23887-cit-0044", "author": "Hjorth-Hansen", "year": "2014", "article-title": "Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)", "journal-title": "Eur J Haematol"}, {"key": "10.1002/ajh.23887-BIB0045|ajh23887-cit-0045", "doi-asserted-by": "crossref", "first-page": "2197", "DOI": "10.1038/leu.2012.134", "article-title": "Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up", "volume": "26", "author": "Larson", "year": "2012", "journal-title": "Leukemia"}, {"key": "10.1002/ajh.23887-BIB0046|ajh23887-cit-0046", "author": "Huang", "year": "2013", "article-title": "Frontline Nilotinib Results In Superior Rates of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis Abstract 1497", "journal-title": "ASH"}, {"key": "10.1002/ajh.23887-BIB0047|ajh23887-cit-0047", "doi-asserted-by": "crossref", "first-page": "379", "DOI": "10.1200/JCO.2013.52.9230", "article-title": "Patient with chronic myeloid leukemia in complete cytogenetic response: What does it mean, and what does one do next?", "volume": "32", "author": "Marin", "year": "2014", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ajh.23887-BIB0048|ajh23887-cit-0048", "doi-asserted-by": "crossref", "first-page": "3898", "DOI": "10.1182/blood-2012-02-410688", "article-title": "A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia", "volume": "120", "author": "Radich", "year": "2012", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0049|ajh23887-cit-0049", "first-page": "1673", "article-title": "Second-generation BCR-ABL kinase inhibitors in CML", "volume": "363", "author": "Simonsson", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0050|ajh23887-cit-0050", "doi-asserted-by": "crossref", "first-page": "2623", "DOI": "10.1056/NEJMc053425", "article-title": "Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia", "volume": "354", "author": "Assouline", "year": "2006", "journal-title": "N Engl J Med"}, {"key": "10.1002/ajh.23887-BIB0051|ajh23887-cit-0051", "doi-asserted-by": "crossref", "first-page": "4981", "DOI": "10.1182/blood-2011-07-369041", "article-title": "Dasatinib inhibits proinflammatory functions of mature human neutrophils", "volume": "119", "author": "Futosi", "year": "2012", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0052|ajh23887-cit-0052", "doi-asserted-by": "crossref", "first-page": "2128", "DOI": "10.1161/CIRCULATIONAHA.111.079921", "article-title": "Pulmonary arterial hypertension in patients treated by dasatinib", "volume": "125", "author": "Montani", "year": "2012", "journal-title": "Circulation"}, {"key": "10.1002/ajh.23887-BIB0053|ajh23887-cit-0053", "author": "Hadzijusufovic", "year": "2013", "volume-title": "Abstract 257"}, {"key": "10.1002/ajh.23887-BIB0054|ajh23887-cit-0054", "doi-asserted-by": "crossref", "first-page": "533", "DOI": "10.1002/ajh.22037", "article-title": "Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML", "volume": "86", "author": "Aichberger", "year": "2011", "journal-title": "Am J Hematol"}, {"key": "10.1002/ajh.23887-BIB0055|ajh23887-cit-0055", "doi-asserted-by": "crossref", "first-page": "1347", "DOI": "10.1093/jnci/djr292", "article-title": "Severe peripheral arterial disease during nilotinib therapy", "volume": "103", "author": "Coutre", "year": "2011", "journal-title": "J Natl Cancer Inst"}, {"key": "10.1002/ajh.23887-BIB0056|ajh23887-cit-0056", "doi-asserted-by": "crossref", "first-page": "317", "DOI": "10.3324/haematol.11680", "article-title": "Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib", "volume": "93", "author": "Franceschino", "year": "2008", "journal-title": "Haematologica"}, {"key": "10.1002/ajh.23887-BIB0057|ajh23887-cit-0057", "doi-asserted-by": "crossref", "first-page": "729", "DOI": "10.1182/blood-2013-12-544015", "article-title": "Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib", "volume": "124", "author": "Hughes", "year": "2014", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0058|ajh23887-cit-0058", "doi-asserted-by": "crossref", "first-page": "1310", "DOI": "10.1038/leu.2013.69", "article-title": "Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis", "volume": "27", "author": "Giles", "year": "2013", "journal-title": "Leukemia"}, {"issue": "Suppl 1", "key": "10.1002/ajh.23887-BIB0059|ajh23887-cit-0059", "article-title": "Long-Term Assessment of Cardiac Toxicity in Patients with Ph+ Leukemias Treated with Bosutinib", "volume": "99", "author": "Gambacorti-Passerini", "year": "2014", "journal-title": "Haematologica"}, {"issue": "5s", "key": "10.1002/ajh.23887-BIB0060|ajh23887-cit-0060", "article-title": "Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib", "volume": "32", "author": "Cortes", "year": "2014", "journal-title": "J Clin Oncol"}, {"key": "10.1002/ajh.23887-BIB0061|ajh23887-cit-0061", "doi-asserted-by": "crossref", "first-page": "391", "DOI": "10.2174/156800912800190965", "article-title": "Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients", "volume": "12", "author": "Breccia", "year": "2012", "journal-title": "Curr Cancer Drug Targets"}, {"key": "10.1002/ajh.23887-BIB0062|ajh23887-cit-0062", "doi-asserted-by": "crossref", "first-page": "511", "DOI": "10.1182/blood-2014-03-566323", "article-title": "Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline", "volume": "124", "author": "Branford", "year": "2014", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0063|ajh23887-cit-0063", "doi-asserted-by": "crossref", "first-page": "1905", "DOI": "10.1002/cncr.11729", "article-title": "Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase", "volume": "98", "author": "Medina", "year": "2003", "journal-title": "Cancer"}, {"key": "10.1002/ajh.23887-BIB0064|ajh23887-cit-0064", "doi-asserted-by": "crossref", "first-page": "5401", "DOI": "10.1182/blood-2008-12-196543", "article-title": "Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study", "volume": "113", "author": "Noens", "year": "2009", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0065|ajh23887-cit-0065", "author": "Jauhar", "first-page": "C1", "year": "2014", "article-title": "Our ailing medical system", "journal-title": "Wall Street J"}, {"key": "10.1002/ajh.23887-BIB0066|ajh23887-cit-0066", "doi-asserted-by": "crossref", "first-page": "872", "DOI": "10.1182/blood-2013-05-501569", "article-title": "European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013", "volume": "122", "author": "Baccarani", "year": "2013", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0067|ajh23887-cit-0067", "doi-asserted-by": "crossref", "first-page": "4439", "DOI": "10.1182/blood-2013-03-490003", "article-title": "The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts", "volume": "121", "author": "Leukemia", "year": "2013", "journal-title": "Blood"}, {"key": "10.1002/ajh.23887-BIB0068|ajh23887-cit-0068", "doi-asserted-by": "crossref", "first-page": "796", "DOI": "10.1056/NEJMp1405158", "article-title": "Updating cost-effectiveness-The curious resilience of the $50,000-per-QALY threshold", "volume": "371", "author": "Neumann", "year": "2014", "journal-title": "N Engl J Med"}], "container-title": ["American Journal of Hematology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fajh.23887", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.23887", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 5]], "date-time": "2018-08-05T23:37:19Z", "timestamp": 1533512239000}, "score": 28.418762, "subtitle": ["First-line treatment in CP-CML"], "issued": {"date-parts": [[2014, 11, 24]]}, "references-count": 68, "journal-issue": {"published-print": {"date-parts": [[2015, 2]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1002/ajh.23887", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0361-8609"], "issn-type": [{"value": "0361-8609", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T09:35:33Z", "timestamp": 1574588133372}, "reference-count": 0, "publisher": "American Medical Association (AMA)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JAMA Oncol"], "published-print": {"date-parts": [[2015, 5, 1]]}, "DOI": "10.1001/jamaoncol.2015.50", "type": "journal-article", "created": {"date-parts": [[2015, 3, 12]], "date-time": "2015-03-12T16:30:43Z", "timestamp": 1426177843000}, "page": "143", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Imatinib\u2014A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015"], "prefix": "10.1001", "volume": "1", "author": [{"given": "Carlo", "family": "Gambacorti-Passerini", "sequence": "first", "affiliation": [{"name": "Department of Health Sciences, University of Milano-Bicocca, Monza, Italy2Section of Hematology, San Gerardo Hospital, Monza, Italy"}]}, {"given": "Rocco", "family": "Piazza", "sequence": "additional", "affiliation": [{"name": "Department of Health Sciences, University of Milano-Bicocca, Monza, Italy"}]}], "member": "10", "container-title": ["JAMA Oncology"], "language": "en", "deposited": {"date-parts": [[2015, 5, 14]], "date-time": "2015-05-14T16:30:59Z", "timestamp": 1431621059000}, "score": 28.418762, "issued": {"date-parts": [[2015, 5, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2015, 5, 1]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1001/jamaoncol.2015.50", "ISSN": ["2374-2437"], "issn-type": [{"value": "2374-2437", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T06:46:10Z", "timestamp": 1575182770899}, "reference-count": 5, "publisher": "Springer Science and Business Media LLC", "issue": "12", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 10, 20]], "date-time": "2005-10-20T00:00:00Z", "timestamp": 1129766400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[2005, 12]]}, "DOI": "10.1038/sj.leu.2403994", "type": "journal-article", "created": {"date-parts": [[2005, 10, 20]], "date-time": "2005-10-20T15:37:58Z", "timestamp": 1129822678000}, "page": "2333-2334", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Response to \u2018D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients\u2019 by Leguay et al"], "prefix": "10.1038", "volume": "19", "author": [{"given": "R G", "family": "Piazza", "sequence": "first", "affiliation": []}, {"given": "V", "family": "Magistroni", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Franceschino", "sequence": "additional", "affiliation": []}, {"given": "C", "family": "Gambacorti-Passerini", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2005, 10, 20]]}, "reference": [{"key": "BF2403994_CR1", "unstructured": "Leguay T, Desplat V, Marit G, Mahon F . D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients. Leukemia, (in press).", "DOI": "10.1038/sj.leu.2403993", "doi-asserted-by": "crossref"}, {"key": "BF2403994_CR2", "doi-asserted-by": "publisher", "first-page": "132", "DOI": "10.1038/sj.leu.2403453", "volume": "19", "author": "RG Piazza", "year": "2005", "unstructured": "Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to imatinib. Leukemia 2005; 19: 132\u2013134.", "journal-title": "Leukemia"}, {"key": "BF2403994_CR3", "doi-asserted-by": "publisher", "first-page": "55", "DOI": "10.1038/sj.thj.6200319", "volume": "5", "author": "HK Al-Ali", "year": "2004", "unstructured": "Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5: 55\u201360.", "journal-title": "Hematol J"}, {"key": "BF2403994_CR4", "doi-asserted-by": "publisher", "first-page": "2093", "DOI": "10.1182/blood-2004-03-1114", "volume": "105", "author": "S Chu", "year": "2005", "unstructured": "Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093\u20132098.", "journal-title": "Blood"}, {"key": "BF2403994_CR5", "doi-asserted-by": "publisher", "first-page": "75", "DOI": "10.1016/S1470-2045(03)00979-3", "volume": "4", "author": "CB Gambacorti-Passerini", "year": "2003", "unstructured": "Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75\u201385.", "journal-title": "Lancet Oncol"}], "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/2403994.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2403994", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2403994.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 27]], "date-time": "2019-03-27T06:03:24Z", "timestamp": 1553666604000}, "score": 28.367744, "issued": {"date-parts": [[2005, 10, 20]]}, "references-count": 5, "journal-issue": {"published-print": {"date-parts": [[2005, 12]]}, "issue": "12"}, "alternative-id": ["BF2403994"], "URL": "http://dx.doi.org/10.1038/sj.leu.2403994", "relation": {"cites": []}, "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}], "subject": ["Anesthesiology and Pain Medicine", "Cancer Research", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T02:13:29Z", "timestamp": 1575166409059}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Blood"], "published-print": {"date-parts": [[2005, 11, 15]]}, "DOI": "10.1182/blood-2005-05-1898", "type": "journal-article", "created": {"date-parts": [[2005, 8, 5]], "date-time": "2005-08-05T00:43:53Z", "timestamp": 1123202633000}, "page": "3377-3379", "source": "Crossref", "is-referenced-by-count": 241, "title": ["The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia"], "prefix": "10.1182", "volume": "106", "author": [{"given": "R. L.", "family": "Levine", "sequence": "first", "affiliation": []}], "member": "234", "container-title": ["Blood"], "language": "en", "deposited": {"date-parts": [[2011, 8, 22]], "date-time": "2011-08-22T14:43:06Z", "timestamp": 1314024186000}, "score": 27.57848, "issued": {"date-parts": [[2005, 11, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2005, 11, 15]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1182/blood-2005-05-1898", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}